Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS3817837 A
Publication typeGrant
Publication date18 Jun 1974
Filing date6 Nov 1972
Priority date14 May 1971
Publication numberUS 3817837 A, US 3817837A, US-A-3817837, US3817837 A, US3817837A
InventorsK Rubenstein, E Ullman
Original AssigneeSyva Corp
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Enzyme amplification assay
US 3817837 A
Images(34)
Previous page
Next page
Description  (OCR text may contain errors)

"United States Patent 3,817,837 ENZYME AMPLIFICATION ASSAY Kenneth E. Rubenstein, Palo Alto, and Edwin F. Ullman, Atherton, Califi, assignors to Syva Corporation, Palo Alto, Calif.

No Drawing. Continuation-impart of abandoned application Ser. No. 143,609, May 14, 1971. This application Nov. 6, 1972, Ser. No. 304,156

Int. Cl. Gtlln 31/14 US. Cl. 195-103.5 R 91 Claims ABSTRACT OF THE DISCLOSURE Novel biological assay method for determining the presence of a specific organic material by employing a modified enzyme for amplification. By employing receptors specific for one or a group of materials (hereinafter referred to as ligands) and binding an enzyme to the ligand or ligand counterfeit to provide an enzyme-bound- ]igand, an extremely sensitive method is provided for assaying for ligands. The receptor when bound to the enzyme-bound-ligand substantially inhibits enzymatic activity, providing for different catalytic efiiciencies of enzyme-bound-ligand and enzyme-bound-ligand combined with receptor.

The receptor, ligand and enzyme-bound-ligand are combined in an arbitrary order and the effect of the presence of ligand on enzymatic activity determined. Various protocols may be used for assaying for enzymatic activity and relating the result to the amount of ligand present.

CROSS-REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of application Ser. No. 143,609, filed May 14, 1971, now abandoned.

BACKGROUND OF THE INVENTION Field of the Invention There is a continually pressing need for rapid, accurate qualitative and quantitative determinations of biologically active substances at extremely low concentrations. The purpose of the determination can be extremely varied. Today, there is a Wide need for determining the presence of drugs or narcotics in body fluids, such as saliva, blood or urine. In addition, in medical diagnosis, it is frequently important to know the presence of various substances which are synthesized naturally by the body or ingested. These include hormones, both steroidal and polypeptides, prostaglandins, toxins, as well as other materials which may be involved in body functions. Frequently, one is concerned with extremely small amounts and occassionally, with very small differences in concentrations.

To meet these needs, a number of ways have been de vised for analyzing for trace amounts of materials. A common method is to use thin layer chromatography (TLC). By determining the flow factors and using specific reagents, the presence of certain materials can be detected; in many instances, the particular material can be isolated and identified quantitatively, for example, by mass spectroscopy or gas phase chromatography. However, thin layer chromatography has a number of deficiencies in being slow, requiring a high degree of proficiency in its being carried out, being subject to a wide range of interfering materials, and suffering from sever fluctuations in reliability. Therefore, the absence of satisfactory alternatives has resulted in intensive research efforts to determine improved methods of separation and identification.

An alternative to thin layer chromatography has been radioimmunoassay. Here, antibodies are employed for specific haptens or antigens. A radioactive ana og employing a radioactive atom of high flux is used ant. bound ice to the antigen. By mixing an antibody with solutions of the hapten or antigen and the radioactive hapten or antigen analog, the radioactive analog will be prevented from binding to the antibody in an amount directly related to the concentration of the hapten or antigen in the solution. By then separating the free radioactive analog from the antibody boimd radioactive analog and determining the radioactivity of the separate components, one can determine the amount of hapten or antigen in the original solution.

The use of radioactive materials is not desirable for a variety of reasons. First, radioactivity creates handling problems and undesirable hazards. Secondly, the preparation of such compounds involves similar hazards, greatly enhanced by the much larger amounts of radioactive materials which are present. Because of their instability, the radioactive materials have only a short life. In addition, the use of radioactive materials requires a license from the Atomic Energy Commission, subjecting the licensee to review by the Commission as to the maintenance of minimum operating standards. These standards may change from time to time, so as to involve added expense and inconvenience to the licensee. Finally, the separation of the bound and unbound radioactive analog is difiicult ad subject to error. See, for example, Abraham, Prelim. Comm, 29, 866 (1969).

Besides the aformentioned materials, assays at extremely low concentrations would be desirable for a variety of pesticides, such as insecticides, bactericides, fungicides, etc., as well as other organic pollutants, both in the air and water. Organic pollutants may be assayed whenever a receptor can be devised and the pollutant is inert to the reagents employed.

Description of the Prior Art Use of radioimmunoassay is described in two articles by Murphy, J. Clin. Endocr. 27, 973 (1967); ibid., 28, 343 (1968). The use of peroxidase as a marker in an immunochemical determination of antigens and antibodies is found in Stanislawski et al., C. R. Acad. Sci. Ser. D. 1970, 271 (16), 1442-5. (CA. 74 1144 B). See also, Nakane, et al., I. of Histochem. and Cytochem. 14, 929 (1967) and Avrameas, Int. Rev. of Cytology, 27, 349 (1970). A general description of thin layer chromatography for assay may be found in Stahl, Thin Layer Chromatography, Springer Verlag, New York, 1969. See also, Peron, et al., Immunologic Methods in Steroid Determination, Appleton, Century Crofts, New York, 1970.

Also of interest are publications by Van Weemen, et al., FEBS Letters 14, 232 (1971), and Engvall, et al., Immunochemistry, 8, 871 (1971) concerned with immunoassays employing enzymes. See also US. Pat. No. 3,654,090. See also, Cinader, Proceedings of the Second Meeting of the Foundation of European Biochemical Societies, Pergamon, Oxford, 1967, vol. 11, chapter four.

SUMMARY OF THE INVENTION Detection of ligands is obtained at extremely low concentrations by using specific receptor sites for the ligand and enzyme amplification of ligand displacement. By bonding a ligand or a ligand counterfeit to an enzyme while retaining enzymatic activity and then combining the enzyme-bound-ligand to a receptor for the ligand, the presence and amount of ligand in an unknown solution may be readily determined. By competition for receptor sites between the enzyme-bound-ligand and the free ligand, the two ligand moieties being added to the receptor simultaneously or sequentially, the difference in enzymatic activity resulting from the presence or absence of ligand may be determined in accordance with a particular analytical scheme. This difference will be related to the amount of ligand present in the unknown solution. Enzymatic activity is easily determined in known ways by following the change in concentration of an enzyme substrate or product of the substrate by standard techniques.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS This invention provides a method for detecting or assaying extremely low concentrations of a wide range of organic materials by relating the presence of a particular unknown to enzymatic activity. An amplification is obtained by having a large number of molecules formed or transformed as a result of the presence of one molecule. This amplification is achieved by bonding the compound to be assayed or a counterfeit of the compound to an enzyme. This assemblage is referred to as an enzymebound-ligand. The particular molecule to be assayed is referred to as a ligand. Te ligand analog will include either a ligand which is modified by replacing a proton with a linking group to bond to the enzyme or a ligand counterfeit which is a ligand modified by other than simple replacement of a proton to provide a linking site to the enzyme. The ligand and the enzyme-bound-ligaud are both capable of binding in a competitive fashion to specific receptor sites. It should also be noted that other compounds of very similar structure may serve as ligands capable of competing for these sites, e.g., morphine glucuronide and codeine will compete with enzyme-boundmorphine for binding to certain types of morphine antibodies. In most instances, this is advantageous in permitting one to assay for a class of physiologically closely related compounds.

Various methods or protocols may be employed in assaying for a wide variety of ligands. Normally, the ligand, enzyme-bound-ligand and receptor will be soluble in the medium employed. The substrate(s) for the enzyme may or may not be soluble in the medium. In some situa tions it may be desirable to provide a synthetic substrate which is not soluble or employ an insoluble natural substrate.

In carrying out the assay, the enzyme-bound-ligand is combined with a high molecular weight receptor which results in inhibition of enzymatic activity. When a ligand and enzyme-bound-ligand are introduced into a solution containing ligand receptor, the enzymatic activity of the solution after the three substances are combined will be affected by the concentration of the ligand present in the solution. That is, the enzyme-bound-ligand and the ligand will compete for the receptor sites. The number of enzymebound-ligand molecules not inhibited by the receptor will be directly related to the number of ligand molecules present in the solution. One can achieve this in two Ways: 1) either by competition, whereby the enzyme-bound-ligand and ligand are introduced to the receptor substantially simultaneously; or (2) the enzyme-bound-ligand or ligand may be first added to the receptor, and the system allowed to come to equilibrium, and then the ligand added or enzyme-bound-ligand added respectively, in effect, to displace the material originally added from the receptor. Since the enzymatic activity will be diminished or inhibited when the enzyme-bound-ligand is bound to the receptor, the enzymatic activity of the solution will be directly related to the amount of ligand present in the solution.

The assay can be carried out, either by considering the effect of ligand on the rate at which enzyme-bound-ligand binds to receptor or the effect of ligand on the equilibrium between the reagents: enzyme-bound-ligand and receptor. Where enzyme-bound-ligand and ligand are present with receptor, one need not wait until equilibrium is achieved between the three species. If one measures the enzymatic activity at a specific time or interval of time from the time of combination of the three species, the enzymatic activity of the assay mixture will be a function of the effect of the ligand on the rate of binding of the enzyme-bound-ligand to the receptor. By determining standards under the same conditions, including the same time interval, employing different concentrations of ligand, a smooth standard curve is obtained.

By measuring the effect of the ligand on rate of binding, rather than the effect on equilibrium, a shorter time interval between the time of combining the reagents and unknown suspected of containing the ligand and the time for the determination will be involved, as compared with waiting until equilibrium is achieved. It is frequently found that reproducible values can be obtained in from 0.1 to 5 minutes after combining the reagents and unknown. The rate of enzymatic activity is usually determined over a short time interval, e.g., one minute. The time interval can be the second, third, etc. minute from the time when the reagents and unknown were combined.

The concentrations of the reagents: the enzyme-boundligand and the receptor, may be varied widely. Normally, the concentration of receptor (based on active sites) and enzyme-bound-ligand will be from about l0- to 10- M, more usually from 10- to 10- M. The lower limit for the concentration of enzyme-bound-ligand is predicated on the minimum amount which can be detected. This will vary with different enzymes as well as different detection systems.

The amount of receptor employed is normally calculated based on receptor sites and will vary with the concentration of enzyme-bound-ligand, the ratio of ligand to enzyme in the enzyme-bound-ligand, and the afiinity of the receptor for the ligand. Usually, there will be at least 1 active receptor site per molecule of enzyme-bound-ligand and less than about 20 active sites per molecule of ligand as enzyme-bound-ligand, but site-ligand molecule ratios may be as high as 1,000 to 1, depending on the type of assay and the affinity of the receptor. Preferably, the ratio of receptor active sites to molecules of enzyme-boundligand will be at least one, usually at least two, and the ratio of active sites to molecules of ligand as enzymebound-ligand will be less than about 5 to 1. The ratio will vary to a great degree depending on binding constants and the amount of ligand suspected of being present. The method of determining binding sites for the receptor will be discussed subsequently in the experimental section.

The enzyme-bound-ligand will usually have molecules of ligand to enzyme subunit ratios on the average over the entire composition in the range of 0101-1001, frequently 0.02-50: l, and more frequently about 0.04-25 1, wherein the number of ligands when the ligand is a protein is expressed as the number of ligand molecules times the number of its component polypeptide chains. For small ligands (less than about 10,000 molecular weight( there will generally be at least one ligand, more usually at least two ligands per enzyme, while with large ligands (greater than about 5,000 molecular weight) there will generally be at least one enzyme per ligand. In the area of overlap, the ratio will depend on the nature of the ligand, among other factors to be discussed.

The number of small ligands per enzyme will be affected to some degree by the molecular Weight of the enzyme. However, normally, the fewer molecules of ligand bound to an enzyme to achieve the desired degree of inhibitability with receptor, the more sensitive the assay. Therefore, the number of small ligands per enzyme will usually not exceed 40, more usually not exceed 30, and will not exceed l ligand per 2,000 molecular weight of enzyme on the average over the entire composition. Usually, the range of ligands will be 1 to 40, more usually 1 to 24, and with random substitution 2 to 20.

With large ligands, there will be on the average not more than one enzyme per 2,000 molecular weight, usually not more than one enzyme per 4,000 molecular weight, and more usually not more than one enezyme per 6,000 molecular weight.

In some instances, a number of enzymes bind together in a stable arrangement to form a multienzyme complex. Because of the juxtaposition of the enzymes, a number of reactions may be carried out sequentially in an efficient manner, providing localized high concentrations of reactants. Therefore, the ligand may be bound to a combination of enzymes, whereby there will be a plurality of enzymes per ligand. If a number of ligands were bound to the multienzyme complex, one could have 1:1 mole ratio of enzymes to ligand, although, in fact, there would be a plurality of enezymes and ligands involved in a single aggregation. The number of enzymes bound together, either as a multienzyme complex or by another mechanism will rarely exceed 20, usually not exceed 10, and commonly be in the range of 2 to 5 enzymes.

All other things being equal, the greater the number of enzymes per large ligand, the greater the sensitivity of the assay. However, the enzymes may interfere with receptor recognition, affect solubility and be deleterious in other ways. Therefore, usually, the number of enzymes bonded to a large ligand will be such that there will be no more than one enzyme polypeptide chain for every 2,000 molecular weight of the ligand.

The concentration of receptor and enzyme will be related to the range of concentration of the ligand to be assayed. The solution to be assayed will be used directly, unless a relatively high concentration of ligand is present. If a high concentration is present, the unknown solution will be diluted so as to provide a convenient concentration. However, in many biological systems of interest, the amount of material being assayed will be relatively small and dilution of the unknown substrate will usually not be required.

To illustrate the subject method, a soluble receptor is employed for a particular ligand. For illustrative purposes, the ligand will be considered the hapten, morphine, and the receptor will be an antibody specific for morphine. It should be noted parenthetically, that antibodies generally recognize molecular shaped and distribution of polyar groups in a ligand, although a portion of the ligand may be significantly modified without preventing recognition. For example, both morphine and its glucuronide can be bound to certain morphine antibodies.

An enzyme is first modified by bonding one or more morphine molecules to the enzyme; a sufficient number of morphine groups are employed so that greater than about 20% inhibition, usually 50% inhibition, and preferably, at least 70% inhibition is obtained when the maximum number of ligands are conjugated to receptor. Complete inhibition is usually neither necessary or desirable. In many instances, all that is required is that there be a measurable difference between completely uninhibited and maximally inhibited enzyme-bound-ligand which would allow for a semi-quantitative or quantitative determination of a ligand through a desired range of concentrations. Any convenient enzyme can be used that will catalyze the reaction of a substrate that can be easily detected and for which a substrate is available which allows for inhibition of the enzyme when bound to receptor.

A solution is prepared of the antibody of the requisite concentration. Only a few microliters of solution are required. The antibody, maintained at a pH at whichit is active in binding morphine, is introduced into a solution of the enzyme-bound-morphine at the desired concentration. The reactivity of the combined antibody and enzymebound-morphone solution can be determined by taking an aliquot, adding it to its substrate under conditions where the enzyme is active, and determining the spectroscopic change as a function of time at a constant temperature. The rate of this change will be the result that should be obtained when there is no morphine present in the unknown solution.

Normally, the ligand and enzyme-bound-ligand reversably bind to receptor, so that the order of addition of reagents is not crucial.

A second aliquot is taken and added to the unknown solution. The unknown solution may contain the substrate and any other additives which are required for enzymatic activity. Alternatively, the unknown solution may first be combined with the antibody-(enzyme-boundmorphine) complex, allowed to come to equilibrium and then mixed with the substrate. In either case the rate of change in the spectrum is determined. A variant of the above method is to add combined enzyme-bound-morphine and unknown solution to the antibody and then add this solution to the substrate. Other obvious variations come readily to mind.

If all concentrations of reagents except morphine are kept constant and several standard solutions of morphine are employed, then one can relate the change in the spectrum over specified periods of time to the morphine concentrations. Obviously, the standardized system can then be used to determine rapidly, accurately, and efliciently the amount of morphine, or any other ligand in the unknown.

The manner of assaying for the enzyme can be widely varied depending on the enzyme, and to some degree the ligand and the medium in which the ligand is obtained. Conveniently, spectrophotometric measurements can be employed, where absorption of a cofactor, a substrate or the product of the substrate absorbs light in the ultraviolet or visible region. However, in many instances other methods of determination may be preferred. Such methods include fluorimetry, measuring luminescence, ion specific electrodes, viscometry, electron spin resonance spectrometry, and metering pH, to name a few of the more popular methods.

The assays will normally be carried out at moderate temperatures, usually in the range of from 10 to C., and more usually in the range of about 15 to 40 C. The pH of the assay solutions will be in the range of about 5 to 10, usually about 6 to 9. Illustrative buffers include (tn'shydroxymethyl)methylamine salt, carbonate, borate and phosphate.

Whether oxygen is present or the assay is carried out in an inert atmosphere, will depend on the particular as say. Where oxygen may be an interferant, an inert atmosphere will normally be employed. Normally, hydroxylic media will be employed, particularly aqueous media, since these are the media in which the enzyme is active. However 0 to 40 volume percent of other liquids may also be present as co-solvents, such as alcohols, esters, ketones, amides, etc. The particular choice of the cosolvent will depend on the other reagents present in the medium, the effect on enzyme activity, and any desirable or undesirable interactions with the substrate or products.

As already indicated, antibodies will frequently recognize a family of compounds, where the geometry and spatial distribution of polar groups are similar. Frequently, by devising the haptenic structure and the method of binding to the antigen when producing the antibodies, the specificity of the antibody can be varied. In some instances, it may be desirable to use two or more antibodies, usually not more than six antibodies, so that the antibody reagent solution will be able to detect an entire group of compounds, e.g., morphine and barbiturates. This can beparticularly valuable for screening a sample to determine the presence of any member of a group of compounds or determining whether a particular class of compounds is present, e.g., drugs of abuse or sex hormones. When combinations of antibodies are used, it will usually be necessary to employ corresponding combinations of enzyme-bound-ligands.

Ligand Turning now to a general consideration of the reagents, the first reagent to be considered is the ligand. Any ligand may be employed for which an appropriate receptor may be found having satisfactory specificity for the ligand. The recent literature contains an increasing number of reports of receptors for an increasingly wide variety of biologically active materials. Compounds for which receptors can be provided range from simple phenylalkylamines, e.g., amphetamine, to very high molecular weight polymers, e.g., proteins.

Among ligands which are drugs, will be compounds which act as narcotics, hypnotics, sedatives, analgesics, antipyretics, anaesthetics, psychotogenic drugs, muscle relaxants, nervous system stimulants, anticholinesterase agents, parasympathomimetic agents, sympathomimetic agents, a-adrenergic blocking agents, antiadrenergic agents, ganglionic stimulating and blocking agents, neuromuscular agents, histamines, antihistamines, S-hydroxytryptamine and antagonists, cardiovascular drugs, antiarrhythmic drugs, antihypertensive agents, vasodilator drugs, diuretics, pesticides (fungicides, antihelminthics, insecticides, ectoparasiticides, etc.), antimalarial drugs, antibiotics, antimetabolites, hormones, vitamins, sugars, thyroid and antithyroid drugs, corticosteroids, insulin, oral hypoglemic drugs, tumor cells, bacterial and viral proteins, toxins, blood proteins, and their metabolites.

(A drug is any chemical agent that atfects living protoplasm. (Goodman & Gilman, The Pharmacological Basis of Therapeutics, 3rd ed., Macmillan, New York (1965).) A narcotic is any agent that produces sleep as well as analgesia.)

Included among such drugs and agents are alkaloids, steroids, polypeptides and proteins, prostaglandins, catecholamines, xanthines, arylalkylamines, heterocyclics, e.g., thiazines, piperazines, indoles, and thiazoles, amino acids, etc.

Other ligands of interest besides drugs are industrial pollutants, flavoring agents, food additives, e.g., preservatives, and food contaminants.

Broadly, the ligands will be organic compounds of from 100 to 100,000 molecular weight, usually of from about 125 to 40,000 molecular weight, more usually 125 to 20,000 molecular weight. The ligand will usually have from about 8 to 5,000 carbon atoms and from about 1 to 3,500 heteroatoms.

A substantial portion of the ligands will be monomers or low order polymers, which will have molecular weights in the range of about 100 to 2,000, more usually 125 to 1,000. Another significant portion of the ligands will be polymers (compounds having a recurring group) which will have molecular Weights in the range of from. about 750 to 100,000, usually from about 2,000 to 60,000, more usually 2,000 to 50,000. For polymers of varying molecular weight, weight average molecular weight is intended.

In some instances, high molecular weight materials will be of interest. For example, blood proteins will generally be in excess of 100,000 molecular weight. In the case of lipoproteins, the molecular weight will be in the range of 3 million to 20 million. The globulins, albumins and fibrinogens will be in the range of 100,000 to 1,000,000.

The ligands will normally be composed of carbon, hydrogen, nitrogen, oxygen, sulfur, phosphorous, halogen, and metals, primarily as their cations, such as the alkali and alkaline earth metals and the metals of Groups IB, IIB, VIIB, and VIIIB, particularly the third row of the periodic chart. Most usually, the ligands will be composed primarily of carbon, hydrogen, nitrogen, oxygen and sulfur.

Structurally, the ligands may be monomers or polymers, acyclic, mono or polycyclic, having carbocyclic or heterocyclic rings. The ligands will have a wide variety of functionalities, such as halo, oxocarbonyl, nonoxocarbonyl, amino, oxy (hydroxy, aryloxy, alyloxy and cycloallyloxy [alyl intends a monovalent aliphatic radical]), thiooxy, dithio, hydrazo, and combinations thereof.

The ligands may be divided into three diiferent categories, based on their biological relationship to the receptor. The first category is antigens, which when introduced into the bloodstream of a vertebrate, result in the formation of antibodies. The second category is haptens, which when bound to an antigenic carrier, and'the hapten bound antigenic carrier is introduced into the bloodstream of a vertebrate, elicit formation of antibodies specific for the hapten. The third category of ligands includes those which have naturally occurring receptors in a living organism and the receptors can be isolated in a form specific for the ligand.

Of course, biological substances which are native to one species and have naturally occurring receptors in that species, may also be haptens when bonded to a protein and introduced into an animal of the same or a different species. Therefore, the classification is somewhat arbitrary in that the ligand may be an antigen as to one species, a hapten as to another species, and may have naturally occurring receptors in a third species.

Antigens are for the most part protein or polysaccharide in nature and foreign to the animal'into which they are injected.

The most important body of ligands for the purposes of the invention are the haptens. Substances which on injection do not give rise to antibodies, but which are able to react with antibodies specifically to produce either precipitation or to inhibit precipitation have been termed haptens. This definition has been used to include not only the simple chemical substances which are determinants of specificity when conjugated to protein, and which inhibit precipitation, but also substances obtained from natural sources such as the pneumococcal type specific polysaccharides and dextran which are not antigenic in the rabbit on primary injection. Kabat, et al., Experimental Immunochemistry, Charles C. Thomas, Springfield, Ill. (1967). In the following discussion the term hapten will be confined to groups artificially introduced into antigenic carriers which promote the formation of antibodies to those groups.

The third group of ligands are those which have naturally occurring receptors. The receptors may be proteins, nucleic acids, such as ribonucleic acid (RNA) or deoxyribonucleic acid (DNA), or membranes associated with cells. Illustrative ligands which have naturally occurring receptors are thyroxine, many steroids, such as the estrogens, cortisone, corticosterone, and estradiol; polypeptides such as insulin and angiotensin, as well as other naturally occurring biologically active compounds. See Murphy, et al., J. Clin. Endocr., 24, 187 (1964), Murphy, ibid., 27, 973 (1957); ibid, 28, 343 (1969); BBA, 176, 262 (1969); McEwen, et al., Nature, 226, 263 (1970); Morgan, et al. Diabetes (1966); Page, et al., J. Clin. Endocr., 28, 200 (1969).

The ligands may also be categorized by the chemical families which have become accepted in the literature. In some cases, included in the family for the purpose of this invention, will be those physiomimetic substances which are similar in structure to a part of the naturally occurring structure and either mimic or inhibit the physio logical properties of the natural substances. Also, groups of synthetic substances will be included, such as the barbiturates and amphetamines. In addition, any of these compounds may be modified for linking to the enzyme at a site that may cause all biological activity to be destroyed. Other structural modifications may be made for the ease of synthesis or control of the characteristics of the antibody. These modified compounds are referred to as ligand counterfeits.

A general category of ligands of particular interest are drugs and chemically altered compounds, as'well as the metabolites of such compounds. The interest in assaying for drugs varies widely, from determining whether individuals have been taking a specific illicit drug," or have such drug in their possession, to determining what drug has been administered or the concentration of the drug in a specific biological fluid.

The drugs are normally of from eight carbon atoms to 40 carbon atoms, usually of from 9 to 26 carbon atoms, and from 1 to 25, usually from 1 to 10 heteroatoms, usually oxygen, nitrogen or sulfur. A large category of drugs have from one to two nitrogen atoms.

One class of drugs has the following basic functionality:

where the lines intend a bond to a carbon atom and wherein any of the carbon atoms and the nitrogen atom may be bonded to hydrogen, carbon or a heterofunctionality. Drugs which have this basic structure include the opiates such as morphine and heroin, meperidine, and methadone.

Another class of drugs are the epinephrine like drugs which have the following basic functionality:

where the lines intend a bond to a carbon atom and wherein any of the carbon atoms and the nitrogen atom may be bonded to hydrogen, carbon or a heterofunctionality. Drugs which have this basis structure include amphetamine, narceine, epinephrine, ephedrine and L-dopa.

The ligand analogs of drugs will usually have molecular weights in the range of 150 to 1,200 more usually in the range of 175 to 700.

Alkaloids The first category is the alkaloids. Included in the category of alkaloids, for the purpose of this invention, are those compounds which are synthetically prepared to physiologically simulate the naturally occurring alkaloids. All of the naturally occurring alkaloids have an amine nitrogen as a heteroannular member. The synthetic al- -kaloids will normally have a tertiary amine, which may or may not be a heteroannular member. The alkaloids have a variety of functionalities present on the molecule,

The opiates are morphine alkaloids. All of these molecules have the following functionality and minimum structures:

wherein the free valences are satisfied by a wide variety of groups, primarily carbon and hydrogen.

The enzyme-bound-ligand analog of these compounds will for the most part have the following minimum skel-- etal structure:

wherein X is a bond or a functionality such as imino, azo, oxy, thio, sulfonyl, oxocarbonyl, nonoxocarbonyl, or combinations thereof. Oxygen will be in the ortho, meta or 3 position. A is an enzyme which is bonded to X at other than its reactive site and retains a substantial portion of its natural enzymatic activity. There will be m ligands bonded through X to the enzyme A.

The enzyme-bound-morphine and its closely related analogs will have the following formula:

won

W -NW wa wa n wherein:

any one of the W groups can be X* or an H of any of the W groups may be replaced by X*, wherein X* is a bond or a linking group;

A* is an enzyme bonded at other than its reactive site, having a number (n) of ligands in the range of 1 to the molecular weight of A* divided by 2,000, usually in the range of 2 to 40;

W is hydrogen or hydrocarbon of from one to eight carbon atoms, particularly alkyl or alkenyl of from 1 to 4 carbon atoms, cycloalkylalkyl of from 4 to 6 carbon atoms, or aralkyl, e.g., methyl, allyl, 3-methylbut- 2-enyl-l, cyclopropylmethyl and fl-phenethyl;

W is hydrogen;

W is hydrogen;

W is hydrogen or taken together with W a divalent radical of from 3 to 6 carbon atoms and 0 to 2 oxygen atoms, forming a six membered carbocyclic ring with the carbon chain to which they are attached, e.g., proplylene 1,3,1-hydroxyprop-2-enylene-'1,3-hydroxypropylene 1,3, 1 acetoxypropylene 1,3, -l-acetoxyprop-2-enylene-1,3, 1-oxopropylene-1,3, 1-oxoprop-2- enylene1,3;

W is hydrogen or hydroxyl;

W is hydrogen, hydroxyl or taken together with W W is hydrogen or methyl;

W is hydrogen, methyl or hydroxyl;

W is hydrogen, hydroxy, acyloxy of from 1 to 3 carbon atoms, e.g., acetoxy, (unless otherwise indicated, acyl intends only nonoxocarbonyl), hydrocarbyloxy of from 1 to 3 carbon atoms, e.g., methoxy, ethoxy, 2-(N- morpholino)ethoxy and glucuronyl; and

W is hydrogen. (It is understood that in all the formulas, except when a minimum or skeletal structure is indicated, unsatisfied valences are satisfied by hydrogen.)

(Hydrocarbyl is an organic radical composed solely of hydrogen and carbon and may be saturated or unsaturated, aliphatic, alicyclic, aromatic or combinations thereof.)

By other than its reactive site, it is intended that the ligand is not bonded to the enzyme at a position which prevents the enzyme substrate, including necessary cofactors, from entering into the reaction catalyzed by the enzyme. It is understood, that with random substitution, the resulting product may include enzyme which has been 1 1 deactivated by ligand bonded at the reactive site, as well as enzyme which is active and has ligand bonded at other than the reactive site.

The close morphine analogs will have the following formula:

A N-w -1 site of ethylenic unsaturation 11 wherein:

any one of the W groups can be X*;

--X*, A*, and n have been defined previously;

W is alkyl of from 1 to 3 carbon atoms, e.g., methyl;

W is hydrogen, hydroxy, oxo or acetoxy;

W is hydrogen or hydroxyl;

W is hydrogen, hydroxyl or taken together with W oxy (-O-); and

W is hydroxy, acetoxy, or alkoxy of from 1 to 3 carbon atoms;

Those preferred compounds having the basic morphine structure will have the following formula:

wherein:

one of W and W is -X**;

when other than X**; W is methyl; and W is hydrogen, methyl, acetyl or glucuronyl; W is hydrogen or acetyl, usually hydrogen; X** is wherein Z is hydrocarbylene of from 1 to 7 carbon atoms, preferably aliphatic, having from 0 to 1 site of ethylenic unsaturation; and Z** is an enzyme, either specifically labelled with n equal to 1 to 2 ligands or randomly (random as to one or more particular available reactive functionalities) labelled 'with n equal to 2 to 30, more usually 2 to 20, the enzyme retaining a substantial proportion of its activity. The enzyme will be of from about 10,000 to 300,000, frequently about 10,000 to 150,000 molecular weight and is preferably an oxidoreductase, e.g., malate dehydrogenase, lactate dehydrogenase, glyoxylate reductase, or glucose 6-phosphate dehydrogenase, or a glycosidase, e.g., lysozyme or amylase.

Illustrative opiates which can be bound to an enzyme include morphine, heroin, hydromorphone, oxymorphone, metopon, codeine, hydrocodone, dihydrocodeine, dihydrohydroxycodeinone, pholcodine, dextromethorphan, phenazocine, and dionin and their metabolites.

Preferred compounds have W or W as -X*A* or have W and W taken together to provide Methadone Another group of compounds having narcotic activityis methadone and its analogs, which for the most part have the following formula: v

wherein any one of the W groups can be X*;

X*, A*, and n have been defined previously;

p is 0 or 1, usually being the same in both instances;

q is 2 or 3;

W is hydrogen;

W and W are hydrogen, alkyl 'of from 1 to 3 carbon atoms, e.g., methyl, or may be taken together to form a six-membered ring with the nitrogen atom to which they are attached, e.g., pentylene-1,5 and 3-oxa or 3- azapentylene lj; I

W is hydrogen or methyl, only one W W is hydrogen;

W is hydrogen or hydroxyl;

W is hydrogen, acyloxy of from 1 to 3 carbon atoms, e.g., propionoxy, or hydroxy (when W and W are both hydroxy, the oxo group is intended); and

W is hydrogen or alkyl of from 1 to 3 carbon atoms,

e.g., ethyl.

{illustrative compounds which can be linked to an enzyme are methadone, dextromoramide, dipipanone, phenadoxone, propoxyphene (Darvon) and acetylmethadol.

Metabolites of methadone and methadone analogs are also included. Among the metabolites for methadone is N- methyl 2-ethyl-3,3-diphenyl-S-methylpyrroline.

Preferred compounds are when W or W is -'X*.

A narrower class of methadone and its analogs are 0 the formula:

being methyl;

any one of the W groups can be X*; X*, A* and n have been defined previously; I W and W are hydrogen;

13 W and W are methyl or are taken together with the nitrogen atom to which they are attached to form a morpholino or piperidine ring; W and W are hydrogen, hydroxy, acetoxy, at least one being hydroxy or acetoxy; and W"' is alkyl of from 1 to 3 carbon atoms.

The methadone derivatives will for the most part have the following formula:

wherein one of W or W is X**; X**, A**, and n have been defined previously; is phenyl; when otherthan X** W is methyl; and W is propyl.

The metabolites of methadone and close analogs will for the most part have the following formula:

wherein:

any one of the W groups can be -X*, X*, A* and n have been defined previously;

45 is phenyl;

W is hydrogen, hydroxyl, methoxyl or acetoxyl, that is of from 0 to 2 carbon atoms, and except when hydrogen of from 1 to 2 oxygen atoms;

W is hydrogen, methyl, or a free valence joined with Wlslll;

W is an unshared pair of electrons;

W is hydrogen or methyl;

W is hydrogen, hydroxy, or taken together with W forms a double bond between the nitrogen atom and the carbon atom to which W and W are respectively attached; and

W is alkyl of from one to three carbon atoms, usually two carbon atoms, or may be taken together with W to form alkylidenyl of from 1 to 3 carbon atoms, usually 2 carbon atoms.

Preferred compounds are those where W or W are X*, particularly W with W as methyl.

Illustrative compounds which may be linked to an enzyme include phenylbenzyl( l-dimethylamino-Z-propyl methyl succinate,

phenylbeuzyl( l-dimethylamino-Z-propyl) methyl oxalate,

diphenyl (Z-dimethylaminol-propyl) methyl maleate,

O-carb oxymethyl-4,4-diphenyl-7dimethylamino-Z- heptanone oxime,

'4,4-diphenyl-7-dimethylamino-3-octyl succinate,

N-( 2,2-diphenyl-3 -methyl-4-morpholinobutyryl) glycine,

3-ethyl-4,4-diphenyl-6-dimethylaminohept-2-enoic acid,

6-keto-7,7-diphenyl-9-diphenyl-9-(dimethylamino) decanoic acid,

N-carboxymethyl 2-ethyl-3,3-diphenyl-5- methylpyrrolidine.

1 4 'Meperidine The third group of compounds which have narcotic activity and are meperidine or meperidine analogs, have for the most part the following formula:

wherein:

any one of the W groups can be ---X*;

X*, A*, and n have been defined previously;

W is hydrogen;

W is hydrogen, alkyl of from 1 to 3 carbon atoms, e.g., methyl, amiophenylalkyl, e.g., 5- (p-aminophenyDethyl, or phenylaminoalkyl, e.g., phenylaminopropyl, (alkyl of from 2 to 3 carbon atoms);

W is alkoxy of from 1 to 3 carbon atoms, e.g., ethoxy;

and

W is hydrogen or methyl.

Illustrative compounds are meperidine, alphaprodine, alvodine and anileridine.

Preferred compounds are those where W or W is X* or a hydrogen of W is replaced with X*.

Indole alkaloids A second group of ligands of interest are based on tryptamine and come within the class of indole alkaloids, more specifically ergot alkaloids. These compounds will have the following minimal structure:

wherein m, X and A have been defined previously.

Other groups of alkaloids include the steroid alkaloids, the iminazolyl alkaloids, the quinazoline alkaloids, the isoquinoline alkaloids, the quinoline alkaloids, quinine being the most common, and the diterpene alkaloids.

For the most part, the alkaloids bonded to an enzyme will be of from about 300 to 1,500 molecular weight, more usually of from about 400 to 1,000 molecular weight. They are normally solely composed of carbon, hydrogen, oxygen, and nitrogen; the oxygen is present as oxy and oxo and the nitrogen present as amino or amido.

Catecholamines was wherein any one of the W groups can be X*;

X*, A* and n have been defined previously;

W is hydrogen or alkyl of from 1 to 3 carbon atoms, e.g.,

methyl;

W is hydrogen, or alkyl of from 1 to 3 carbon atoms,

e.g., methyl;

W and W are hydrogen;

W is hydrogen, hydroxy, dimethoxycarboxyphenacyl,

and dimethoxy-a-phthalidyl;

W and W are hydrogen, one of which may be taken with W to form a bond, and when W and W are taken together, each of W and W and W and W may be taken together to form a double bond;

W is hydrogen or alkoxy of from 1 to 3 carbon atoms;

e.g., methoxy;

W and W are hydroxy or alkoxy of from 1 to 3 carbon atoms, e.g., methoxy.

Illustrative compounds include cotainine, narceine, noscapine and papaverine.

Preferred compounds are where W", W or W are X* or have a hydrogen replaced with X*.

A group of compounds related to the catecholamines are epinephrine, amphetamines and related compounds. These compounds have the formula:

wherein:

any one of the W groups can be -X*;

X*, A* and n have been defined previously;

W and W are hydrogen or alkyl of from 1 to 3 carbon atoms, e.g., methyl and isopropyl, preferably one is hydrogen;

W is hydrogen, alkyl of from 1 to 3 carbon atoms, e.g., methyl and ethyl, or may be taken together with W to form a ring having six annular members with the nitrogen as the only heteroatom;

W is hydrogen, hydroxyl, carbomethoxy, or may be taken together with W to form a morpholine ring;

W is carbomethoxy, when W and W are taken to gether to form a piperidine ring; and

W and W are hydrogen, hydroxyl or alkoxyl of from 1 to 3 carbon atoms.

Illustrative compounds which can be bonded to an enzyme are ephedrine, epinephrine, L-dopa benzidrine (amphetamine), paredrine, methamphetamine, methyl phenidate and norephedrine.

Illustrative compounds which can be linked to an enzyme include 3-(3',4'-dihydroxypheny1) -3-hydroxypropionic acid, N- )3- )3, 3 ,4 trihydroxyphen) ethyl) N-methyl glycine, N 1-phenyl-2-propyl) oxalamic acid.

-( 1-phenyl-2-methylamino-l-propyl) glycolic acid, p-(Z-methylaminopropyH phenoxyacetic acid,

N- l'-phenyl-2'-propyl) glycine, 4-methylamino-4-phenylvaleric acid,

para- (Z-aminopropyl- 1 phenoxyacetic acid,

1 6 4-methylamino-5-phenylvaleric acid, and 3-amino-4-phenylbutyric acid.

Where W and W are hydrogen, preferred compounds will have the following formula:

in 43 W42 any one of the W groups can be --X*;

X*, A* and n have been defined previously;

W and W are hydrogen or alkyl of from 1 to 3 car'- bon atoms, preferably one is hydrogen;

W is hydrogen, -methyl or may be taken together with W to form a piperidine ring;

W is hydrogen, hydroxyl or carbomethoxy; and

W is hydrogen.

Where W and W are oxy, the preferred compounds have the following formula: j

W43 W42" JJH- HN wherein any one of the W groups can be X*;

X*, A* and n have been defined previously; W W and W are hydrogen or methyl; W is hydrogen or hydroxyl; and

W and W are hydroxyl or methoxyl.

Closely related compounds to the amphetamines are those where a saturated five or six membered ring is substituted for the phenyl ring. These compounds will have the following formula:

any one of the W groups is -X*; W have been defined above; W is hydrogen or methyl;

W is hydrogen or hydroxyl; W is hydrogen; and

b is an integer of from four to five.

Of particular interest are those amphetamines bonded to enzymes of the following formula:

wherein one of W W and W is --X**; when other than -X** Barbiturates A wide class of synthetic drugs which finds extensive and frequent abuse are the barbiturates. These compounds are synthetically readily accessible and their use only dif 1 7 ficultly policed. The compounds which find use will com within the following formula:

wan

WEL'IL w 51 any one of the W groups can be -X*;

X*, A*, and n have been defined previously;

W is hydrogen, alkyl of from 1 to 3 carbon atoms, e.g.,

methyl or alkali metal, e.g., sodium;

W and W are hydrogen, alkyl, alkenyl, cycloalkyl, cy-

cloalkenyl, or aryl hydrocarbon of from 1 to 8, more usually 1 to 6 carbon atoms, e.g., ethyl, n-butyl, u-methylbutyl, isoamyl, allyl, A -cyclohexenyl, and phenyl;

W is hydrogen, or alkali metal, e.g., sodium;

W is oxygen or sulfur.

wherein:

Of particular interest are those barbiturates bonded to an enzyme of the formula:

0 ts, \g was wherein one of W and W is X**; when other than -X**:

W is hydrogen, methyl or alkali metal, e.g., sodio; and

W is hydrocarbon of from 1 to 8 carbon atoms, having from 0 to 1 site of ethylenic unsaturation;

W is hydrocarbon of from 2 to 8 carbon atoms, having from 0 to 1 site of ethylenic unsaturation;

is ZCO, wherein Z is hydrocarbylene of from 1 to 7 carbon atoms, usually aliphatic, having from 0 to 1 site of ethylenic unsaturation;

A** and n have been defined previously.

Glutethimide Another compound of interest is g-lutethimide, wherein the enzyme bound analog will have the following formula:

Wa t! wherein:

any one of the W groups can be -X*;

X*, A* and n have been defined previously;

W and W are hydrogen; and

W' is lower alkyl of from 1 to 3 carbon atoms, e.g.,

ethyl.

Cocaine A drug of significant importance in its amount of use is cocaine. The enzyme bound cocaine or cocaine metabohtes or analogs, such as ecgonine, will for the most part have the following formula:

CHO OW JJH-OW) A CHz- 0 wherein: l 1' any one of the W groups can be X*;

X*, A* and n have been defined previously;

W is hydroxy, methoxy, amino or methylamino;

W is hydrogen or benzoyl; and

W is hydrogen or alkyl of from 1 to 3 carbon atoms, e.g.,

methyl.

Of particular interest are those ecgonine derivatives (including cocaine derivatives) of the formula:

- c ow N-W -ow A" wherein one of W and W is --X*; when other than W is hydrogen or benzoyl; and W is methyl;

W is hydroxy or methoxy; X** is wherein Z is methylene or carbonyl; or-Z-CO wherein Z is hydrocarbylene of from 1 to 7 carbon atoms, usually aliphatic, having from 0 to 1 site of ethylenic unsaturation;

A** and n have been defined previously.

Diphenyl Hydantoin Another compound of interest is the antiepileptic drug diphenyl hydantoin. This compound and its analogs will have the fol-lowing formula:

wherein any one of the W groups can be --X*;

X*, A* and n have been defined previously; is phenyl;

W W and W are hydrogen.

Marijuana Because of its ready availability and widespread use, tetrahydrocannabinol (the active ingredient of marijuana) and its congeners, cannabidiol and cannabinol and their metabolites are compounds of great interest, where a simple assay method would be of importance. The comformula wall) -3 sites of ethylenie unsaturation,

(particularly A", A" and A wherein any one of the W groups can be -X*;

X*, A* and n have been defined previously;

W is hydrogen or carboxyl;

W is hydroxyl or methoxyl;

W is hydrogen;

W is pentyl or hydroxypentyl;

W is hydrogen, methyl, or the two W s may be taken together to form a carbocyclic ring of from to 6 annular members; and

W is methyl, hydroxymethyl or carboxyl.

Tranquilizers A number of compounds have tranquilizer effects and because of their misuse or abuse do provide opportunities where the determination could be of use.

The first tranquilizer of interest is Meprobamate, also known as Miltown or Equanil. This compound and related analogs have the following formula:

wherein:

any one of the W groups can be -X*; X*, A* and n have been defined previously; W and W are amino.

The next group of tranquilizers are benzdiazocycloheptanes and are known as Librium, Valium, Diazepam, or Oxazepam. These compounds and their related analogs will have the following formula:

Wail was: W080 I N W m Wull wherein:

20 The next group of compounds are the phenothiazines of which chlorpromazine is a member. These compounds will for the most part have the following formula:

Wm nwsil will wherein any one of the W groups can be -X*;

X*, A*, and n have been defined previously;

W is hydrogen, alkyl of from 1 to 6 carbon atoms, dialkylaminoalkyl of from 4 to 8 carbon atoms, e.g., 3(dimethylamino)propyl; N-hydroxyalkyl (alkyl of from 2 to 3 carbon atoms), N'-piperazinoalkyl (alkyl of from 2 to 3 carbon atoms), e.g., N-hydroxyethyl N'- piperazinopropyl; N-alkyl (alkyl of from 1 to 3 carbon atoms) N-piperazinoalkyl (alkyl of from 2 to 3 carbon atoms), e.g., N-methyl N-piperazinopropyl; and 2-(N- alkyl)-piperidinoalkyl, wherein the N-alkyl is of from 1 to 3 carbon atoms and the other alkyl is of from 2 to 3 carbon atoms, e.g., Z-(N-methyl)-piperidinoethyl, there being at least two carbon atoms between the heteroatoms;

W is hydrogen, chloro, trifiuoromethyl, alkylmer'capto of from 1 to 3 carbon atoms, e.g., methylmercapto and acyl of from 1 to 3 carbon atoms, e.g., acetyl; and

W and W are hydrogen.

Amino acids, polypeptides and proteins The next group of compounds are the amino acids, polypeptides and proteins. For the most part, the amino acids range in carbon content from 2 to 15 carbon atoms, and include a variety of functional groups such as mercapto, dithio, hydroxyl, amino, guanidyl, pyrrolidinyl, indolyl, imidazolyl, methylthio, iodo, diphenylether, hydroxyphenyl, etc. These, of course, are primarily the amino acids related to humans, there being other amino acids found in plants and animals.

Polypeptides usually encompass from about 2 to amino acid units (usually less than about 12,000 molecular weight). Larger polypeptides are arbitrarily called proteins. Proteins are usually composed of from 1 to 20 polypeptide chains, called subunits, which are associated by covalent or non-covalent bonds. Subunits are normally of from about 100 to 400 amino acid groups (-10,000 to 50,000 molecular weight).

Individual polypeptides and protein subunits will normally have from about 2 to 400, more usually from about 2 to 300 recurring amino acid groups. Usually, the polypeptides and protein subunits of interest will be not more than about 50,000 molecular weight and greater than about 750 molecular weight. Any of the amino acids may be used in preparing the polypeptide. Because of the wide variety of functional groups which are present in the amino acids and frequently present in the various naturally occurring polypeptides, the enzyme bonded compound can be bonded to any convenient functionality. Usually, the enzyme bonded compound can be bonded to a cysteine, lysine or arginine, tyrosine or histidine group, although serine, threonine, or any other amino acid with a convenient functionality, e.g., carboxy and hydroxy, may be used.

For the most part, the enzyme-labeled polypeptides will have the following formula:

an amino acid residue, r being an integer of from 1 to 1,000, more usually of from 1 to 500, and most com 21 monly of from 2 to 100. r is an integer of at least one and not greater than the molecular weight of the polypeptide divided by 2,000.

Illustrative amino acids include glycine, alanine, serine, histidine, methionine, hydroxyproline, tryptophan, tyrosine, thyroxine, ornithine, phenylalanine, arginine, and lysine. Polypeptides of interest are ACTH, oxytocin, lutenizing hormone, insulin, Bence-Iones protein, chorionic gonadotropin, pituitary gonadotropin, growth hormone, rennin, thyroxine bonding globulin, bradykinin, angiotensin, follicle stimulating hormone, etc.

In certain instances, it will be desirable to digest a protein and assay for the small polypeptide fragments. The concentration of the fragment may then be related to the amount of the original protein.

Steroids Another important group of compounds which find use in this invention are the steroids, which have a wide range of functionalities depending on their function in the body. In addition to the steroids, are the steroidmimetic substances, which while not having the basic polycyclic structure of the steroid, do provide some of the same physiological effects.

The steroids have been extensively studied and derivatives prepared which have been bonded to antigenic proteins for the preparation of antibodies to the steroids. Illustrative compounds include: 17B-estradiol-6-(O-carboxymethyl-oxime)-BSA (bovine serum albumin) (Exley, et al., Steroids 18 593, (1971); testosterone-3-oxime derivative of BSA (Midgley, et al., Acta Endocr. 64 supplement 147, 320 (1970) and progesterone-3-oxime derivative of BSA (Midgley, et al., ibid.)

For the most part, the steroids used have the following formula:

wherein m, X and A have been defined previously. Usually, the enzyme will be bonded to the A, B, or C rings, at the 2, 3, 4, 6 or 11 positions, or at the 16 or 17 positions of the D ring or on the side chains at the 17 position. Of particular interest is where X is bonded to the 6 position. The rings may have various substituents, particularly methyl groups, hydroxyl groups, oxocarbonyl groups, ether groups, and amino groups. Any of these groups may be used to bond the enzyme to the basic ring structure. For the most part, the steroids of interest Will have at least one, usually 1 to 6, more usually -1 to 4 oxygen functionalities, e.g., alcohol, ether, esters, or keto. In addition, halo substitutents may be present. The steroids will usually have from 18 to 27 carbon atoms, or as a glycoside up to 50 carbon atoms.

The rings may have one or more sites of unsaturation, either ethylenic or aromatic and may be substituted at positions such as the 6, 7 and 11 positions with oxygen substituents. In addition, there may be methyl groups at the and 13 positions. The postion marked with a Z, 17, may be and will be varied widely depending on the particular steroid. Z represents two monovalent groups or one divalent group and may be a carbonyl oxygen, an hydroxy group, an aliphatic group of from 1 to 8 carbon atoms, including an acetyl group, an hydroxy-acetyl group, carboxy or carboxyalkyl of from 2 to 6 carbon atoms, an acetylenic group of from 2 to 6 carbon atoms or halo substituted alkyl or oxygenated alkyl group or a group having more than one functionality, usually from 1 to 3 functionalities.

For the second valence of Z, there may be a H or a second group, particularly hydroxyl, alkyl, e.g., methyl, hydroxyalkyl, e.g., hydroxymethyl; halo, e.g., fluoro or chloro, oxyether; and the like.

These steroids find use as hormones, male and female (sex) hormones, which may be divided into oestrogens, gestrogens, antrogens, a-drenocortical hormones (glucocorticoids), bile acids, cardiotonic glycosides and aglycones, as well as saponins sapogenins.

Steroid mimetic substances, particularly sex hormones are illustrated by diethyl stilbestrol.

The sex hormones of interest may be divided into two groups; the male hormones (androgens) and the female hormones (oestrogens).

The androgens which find use will have the following formula:

f woo g 0-1 site of ethylenic unsaturation J wherein:

any one of the W groups can be X*;

X*, A* and n have been defined previously;

W is hydrogen, or hydroxyl;

W is hydrogen, methyl or hydroxyl (when two groups bonded to the same carbon atom are hydroxyl, oxo is intended);

W and W are hydrogen or hydroxyl, at least one of W is hydroxy (either as hydroxy or oxo);

W is hydrogen, or two W s may be taken together to form a double bond;

W is methyl; and

W is hydrogen.

win we o-1 site of ethylenie unsaturation w7a wu,

wherein:

any one of the W groups can be -X*;

X*, A* and n have been defined previously;

W and W are hydrogen, ethinyl or hydroxyl (when two hydroxyls are bonded to the same carbon atom, oxo is intended);

W is hydrogen or hydroxyl;

23 W" is hydroxyl or alkoxyl of from 1 to 3 carbon atoms; W" is hydrogen or two W s may be taken together to form a double bond; and W is hydrogen.

Illustrative compounds which may be bonded to an enzyme are equilenin, fi-estradiol, estrone, estriol, and 17- a-ethinyl-estradiol.

The oestrogens have an aromatic A ring and for the most part have the following formula:

wherein any one of the W groups can be X*;

X*, A* and n have been define-d previously;

W" and W are hydrogen, ethinyl or hydroxyl (when two hydroxyls are bonded to the same carbon atom, oxo is intended);

W is hydrogen or hydroxyl;

W is hydroxyl or al'koxyl of from 1 to 3 carbon atoms;

W is hydrogen or two W s may be taken together to form a double bond; and

W" is hydrogen.

Illustrative compounds which may be bonded to an enzyme are equilenin, ,B-estradiol, estrone, estriol, and 17-a-ethinyl-estradiol.

Illustrative compounds which may be linked to an enzyme include 3-carboxymetl1yl estradiol, 2-chloromethylestrone, estrone glutarate, O-carboxymethyloxime of 6-1ketoestradiol, equilenyl N-carboxymethyl thiocarbamate.

Another class of hormones are the gestogens which have the following formula:

wherein:

any one of the W groups can be X*;

X*, A* and n have been defined previously;

W and W are hydrogen or hydroxyl, at least one being hydroxyl (where two hydroxyl groups are bonded to the same carbon atom, oxo is intended);

W is hydrogen or hydroxyl;

W and W are hydrogen or hydroxyl, at least one being hydroxyl; and

W is hydrogen, or two W s may be taken together to form a double bond.

Illustrative compounds which may be bonded to an enzyme include progesterone, pregnenolone, allopregnane- 3az20a-diol and allopregnan-3a-ol-20-one.

Illustrative compounds which may be linked to an enzyme include -progesterone O-carboxymethyl oxime, pregn-4-en-20-0n-3ylidinylmethylenecarboxylic acid, O-carboxymethyl progesterone 3-oxime, pregnenolonyl tartrate,

O-pregnenolonyl tartrate,

O-pregnenolonyl lactic acid, and allopreganane-3-carboxyrnethyl-20-ol.

24 The next important group of steroids is the corticosteroids which includes both the mineralcorticoids and the glucocorticoids. These compounds have the following formula:

\i/ Wv5 wan ivw won 0-1 site of ethylenic unsaturation J I1 wherein any one of the W groups can be X*;

X*, A* and n have been defined previously;

W is hydrogen or hydroxyl;

W and W are hydrogen or hydroxyl, at least one of which is hydroxyl (when two hydroxyl groups are bonded to the same carbon atom, oxo is intended);

W is hydrogen or hydroxyl;

W W W and W are hydrogen or hydroxyl, at

least one of W and W is hydroxyl;

W is methyl or formyl; and

W is hydrogen or two W s may be taken together to form a double 'bond.

0-1 site of ethylenlc unsaturatlon o 0 W I (L wherein:

any one of the W groups can be -X*;

X*, A* and n have been defined previously;

W W W and W are hydrogen, hydroxy], or a glycoside, at least one being hydroxyl or a sugar, mostly as a glycoside. The sugars include xylose, glucose, cymarose, rhamnose, and galactose.

Also of interest are the saponins and sapogenins derived from plants. These compounds have a spiro ring structure at C22.

Sugars The next group of compounds are the sugars and saccharides are combinations of various sugars to form dimers, tn'mers and high molecular weight polymers, referred to as polysaccharides.

Prostaglandin Another group of compounds of biological importance are the prostaglandins. These compounds when bonded to enzymes have for the most part the following formula:

-1 site of ethylenic unsaturation Cs o-n 01 site of ethylenic unsaturation wherein any one of the W groups can be X*;

X*, A* and n have been defined previously;

W is hydrogen or hydroxyl;

W and W are hydrogen or hydroxyl, (where two hydroxyl groups are bonded to the same carbon atom, oxo is intended);

W is hydrogen or hydroxyl; and

W" is hydroxyl, amino or an oxy group of from 1 to 6 carbon atoms, e.g., alkoxy.

Miscellaneous Included is this group are the antibiotics such as penicillin, chloromycetin, actinomycetin, tetracycline, terramycin, and nucleic acids or derivatives, such as nucleosides and nucleotides.

Also of interest is serotonin which is 3-(2'-aminoethyl)-5-hydroxyindole. X* may be bonded at either of the amino nitrogen atoms or the hydroxyl group.

Of course, many of the compounds which are of interest undergo metabolic changes, when introduced into a vertebrate. The particular physiological fluid which is tested may have little, if any of the original compound. Therefore, the original presence of the compound might only be detectable as a metabolite. In many instances, the metabolite may be the glucuronide, either oxy or 0x0 derivative of the original compound. In other instances, the original compound may have undergone oxidation, e.g., hydroxylation, reduction, acetylation, deamination, amination, methylation or extensive degradation. Where the metabolite still retains a substantial portion of the spatial and polar geometry of the original compound, it will be frequently possible to make the ligand analog based on either the original compound or metabolite. Where the metabolite is distinctively different than the original compound, the ligand analog will be based on the metabolite.

Of particular interest as metabolites, particularly of the steroids, are the sulfates and glucuronides.

Besides meabolites of the various drugs, hormones and other compounds previously described, of significant interest are metabolites which relate to diseased states. Illustrative of such compounds are spermine, galactose,

26 phenylpyruvic acid and porphyrin Type 1, which are believed to be diagnostic of certain tumors, galactosemia, phenylketonuria and congenital porphyra, respectively.

Two compounds of interest which are metabolites of epinephrine are vanillylmandelic acid and homovanillic acid. With these compounds, either the hydroxyl or carboxyl groups can be used as the site for X*.

Another general category of interest is the pesticides, e.g., insecticides, fungicides, bacteriocides and nematocides. Illustrative compounds include phosphates such as malathion, DDVP, dibrom; carbamates, such as Sevin, etc.

Since many of the biologically active materials are active in only one stereoisomeric form, it is understood that the active form is intended or the racemate, where the racemate is satisfactory and readily available. The antibodies will be specific for Whatever form is used as the hapten.

Enzymes (A) Enzymes vary widely in their substrates, cofactors, specificity, ubiquitousness, stability to temperature, pH optimum, turnover rate, and the like. Other than inherent factors, there are also the practical considerations, that some enzymes have been characterized extensively, have accurate reproducible assays developed, and are com mercially available. In addition, for the purposes of this invention, the enzymes should either be capable of specific labelling or allow for efiicient substitution, so as to be useful in the subject assays. By specific labelling is intended selective labelling at a site in relationship to the active site of the enzyme, so that upon bindin of the receptor to the ligand, the enzyme is satisfactorily inhibited. By allowing for efiicient substitution to be useful in the subject assay, it is intended that the enzyme be inhibited sufliciently when the ligand is bound to the receptor, and that the degree of substitution required to achieve this result does not unreasonably diminish the turnover rate for the enzyme nor substantially change the enzymes solubility characteristics.

From the standpoint of operability, a very wide variety of enzymes can be used. But, as a practical matter, there will be a number of groups of enzymes which are preferred. Employing the International Union of Biochemists (I.U.B.) classification, the oxidoreductases (1.) and the hydrolases (3.) will be of greatest interest, while the lyases (4.) will be of lesser interest. Of the oxidoreductases, the ones acting on the CHOH group, the aldehyde or keto group, or the CH-NH group as donors (1.1, 1.2, and 1.4 respectively) and those acting on hydrogen peroxide as acceptor (1.l1) will be preferred. Also, among the oxidoreductases as preferable will be those which employ nicotinamide adenine dinucleotide, or its phosphate or cytochrome as an acceptor, namely 1.x.l and 1.x.2, respectively under the I.U.B. classification. Of the hydrolases, of particular interest are those acting on glycosyl compounds, particularly glycoside hydrolases, and those acting on ester bonds, both organic and inorganic esters, namely the 3.1 and 3.2 groups respectively, under the I.U.B. classification. Other groups of enzymes which might find use are the transferases, the lyases, the isomerascs, and the ligases.

In choosing an enzyme for commercialization, as compared to a single or limited use for scientific investigation, there will be a number of desirable criteria. These criteria will be considered below.

The enzyme should be stable when stored for a period of at least three months, and preferably at least six months at temperatures which are convenient to store in the laboratory, normally 20 C. or above.

The enzyme should have a satisfactory turnover rate at or near the pH optimum for binding to the antibody, this is normally at about pH 6-10, usually 6.0 to 8.0. Preferably, the enzyme will have the pH optimum for the 27 28 turnover rate at or near the pH optimum for binding of to 150,000 molecular weight, and frequently from 10,000 the antibody to the ligand. to 100,000 molecular weight. Where an enzyme has a A product should be either formed or destroyed as a plurality of subunits the molecular weight limitations result of the enzyme reaction which absorbs light in the refer to the enzyme and not to the subunits. ultraviolet region or the visible region, that is the range For synthetic convenience, it is preferable that there of about 250-750 mm, preferably 300-600 nm. be a reasonable number of groups to which the ligand Preferably, the enzyme should have a substrate (includmay be bonded, particularly amino groups. However, ing cofactors) which has a molecular weight in excess of other groups to which the ligand may be bonded include 300, preferably in excess of 500, there being no upper hydroxyl groups, thiols, and activated aromatic rings, e.g., limit. The substrate may either be the natural substrate, phenolic. or a synthetically available substrate. Therefore, enzymes will preferably be chosen which are Preferably, the enzyme which is employed or other sufiiciently characterized so as to assure the availability enzymes, with like activity, will not be present in the of sites for linking, either in positions which allow for fluid to be measured, or can be easily removed or deactiinhibition of the enzyme when the ligand is bound to vated prior to the addition of the assay reagents. Also, antibody, or there exist a sufficient number of positions one would Want that there not be naturally occurring as to make this occurrence likely. inhibitors for the enzyme present in fluids to be assayed. A list of common enzymes may be found in Hawk,

Also, although enzymes of up to 600,000 molecular et 211., Practical Physiological Chemistry, McGraw-I-Iill weight can be employed, usually relatively low molecular Book Company, New York (1954), pages 306 to 307. weight enzymes will be employed of from 10,000 to That list is produced in total as follows, including the 300,000 molecular weight, more usually from about 10,000 source of the enzyme, the subtrate and the end products.

Name and class Distribution Substrate End-products Hydrolases carbohydrascs: Carbohydrates 1. Amylase Pancreas, saliva, malt, etc Starch, dextrin, etc Maltese and dextriris. 2. Lactase-. Intestinal Juice and mucosa. Lactose Glucose and galactose. 3. Maltase lntestinaljuice, yeast, etc Maltose. Glucose. 4. Sucr do Sucrose". Glucose and fructose. 5. Emulsin Plants B-Glucosides Glucose, etc.

N ucleases: Nucleic acid and derivatives 1. Polynuclcotidase Pancreatitciuice, intestinal Nucleic acid Nucleotides.

Juice, e -c. 2. Nucleotidase Inttestinaliuice and other Nucleotides Nucleotides and phosphoric acid.

ISSUES. 3. Nucleotidasc Animal tissues .do Carbohydrate and bases.

Amidases: Amino compounds and amides 1. Argiiiase Liver Arginine Ornithine and urea. 2. Urease Ba cteria, soybean, Jack bean, Urea Carbon dioxide and ammonia.

e c. 3. Glutairiinase Liver, etc Glutamine Glutamic acid and ammonia. 4. Transamiuase Animal tissues Glutamic acid and oxalacctic acid, e-Ketoglutaric acid, aspartic acid, ctc.

Purine deaminases: Purine bases and derivatives 1. Adenase- Animal tissues Adenine.. Hypoxanthinc and ammonia. 2. Guanase ..do Guanine- Xautliiiic and ammonia.

Pcptidases: Peptides 1. Aminopolypeptidase. Yeast, intestines, etc Polypeptides Simpler peptides and amino acids. 2. Carboxypeptidase Pancreas. .do Do. 3. Dipeptidase Pllginttar d animal tissues and Dipeptides Amino acids.

6H3. 4. Prolinase Animal tissues and yeast Proline peptides Proline and simpler peptides.

Proteinascs: Proteins 1. Pepsin Gastn'el'uice Pro Pro P peptones, etc. 2. Trypsin Pancreatic Juice Proteins, proteoses, and peptones Polypeptides and amino acids. 3. Cathepsi Animal tissues Protein Proteoses, and peptones. 4. Rennin- Calf stomach Casein- Paracasein. 5. Chymotrypsin Pancreatic juice Proteins, proteosm and peptones Polypeptides and amino acids. 6. Papain Papaya, other plants do 7. Ficin Fig sap Proteins Proteoses, etc.

Esters Alcohols and acids Esterases:

1. Li ase Pancreas, castor bean, etc Fats Glycerol and fatty acids. 2. Esterases.... Liver, etc Ethyl butyrate, etc--. Alcohols and acids. 3. Phosphatases. Plant and animal tissues Esters of phosphoric acid.- Phosphate and alcohol. 4. Suliatases Animal and plant tissues Esters of sulfuric acid"--. Sulfuric acid and alcohol. 5, Cholinosfarase Blood, tissues Acetylchcline Choline and acetic acid. Iron enzymes:

1. Catalase All living organisms except a Hydrogen peroxide Water and oxygen.

few species of microorganisms. 2. Cytochrome nridase do Reduceifi cytochrome C in the pres- Oxidized cytochrome C and water.

ence 0 oxygen. 3. Peroxidase Nearly all plant cells A large number of phenols, aromatic Oxidation product of substrate and amines, etc. in the presence of H202. wa er. Copper enzymes:

1. Tyrosinase (poly-phcnol- Plant and animal tissues Various phenohe compounds Oxidation product of substrate.

oxidgse, monoplienoloxidase 2. Ascorbic acid oxidase Plant tissues Ascorbic acid in the presence of oxygen. Dehydroascorbic acid. Enzymes containing coenzymes I and/or II:

1. Alcohol dehydrogenase Animal and plant tissues Ethyl alcohol and other alcohols Acetaldehyde and other aldchydcs. 2. Malic dehydrogenase.-.- do... L( malic acid OXalacetic acid 3. Isocitric dehydrogenasedo.-- L-isocitric acid..-- Oxalosuccinic acid. 4. Lactic dehydrogeiiase Animal tissues and ye Lactic acid Pyruvic acid. 5. fi-Hydrorylbutyric dehy- Liver, kidneys, and heart L-B-hydroxybuty'ric acid Acetoacetic acid.

drogenase. 6. Glucose dehydrogenase... Animal tissues D-glucose D-gluconic acid.

TABLE-Continued Name and class Distribution Substrate End-products 7. Bobison ester dehydrog- Erythrocytes and yeast Robisonester(hexose-fi-phosphate) Phosphohexonic acid.

8119.39. 8. d(Illycerophosphate dehy- Animal tissues Glycerophosphate Phosphoglyceric acid.

ogenase. 9. Aldehyde dehydrogenase... Liver Aldehydes Acids. Enzymes which reduce cytochrome:

1. Succinic dehydrogenase Plants, animals and microor- Succinic acid Fuman'c acid.

(as ordinarily prepared). ganisms Yellow enzymes:

1. Warburgs old yellow Yeast Reduced coenzyme Il Oxidized coenzyme II and reduced yellow enzyme. enzyme. 2. Diaphorase Bacteria, yeasts, higher plants, Reduced coenzyme 1 Oxidized coenzyme I and redu ed yellow and animals. diaphorase. 3. Haas enzy Yeast. Reduced coenzyme II Oi1ridized coenzyme II and red d yel- OW enzyme. 4. Xanthine oxidase Animal tissues Hypoxanthine xanthine, aldehydes, Xanthine, uric acid, acids, oxidized reduced coenzyme I, etc. enzyme I, etc. in presence of air, H201. 5. D-amino acid mri .do D-amino acids plus Oz a-Keto-acids plus NH: plus H 0 6. L-amino acid oxidases Animals, snake venoms Iramino acids Keto acids and ammonia. 7. TPN-cytochrome 0 Yeast, liver Reduced coenzyme II and cytochrome Oxidized coenzyme I and reduc d cytoreductase. C. chrome C. 8. DPN cytochrome 0 Liver, yeast Reduced coenzyme I and cytochrome Do.

reductase. O. Hydrases:

1. Fumarase Living organisms in general Fumanc acid plus 1120 L-malic acid. 2. Aconitase Animals and plants Citric acid cis-Aconitic acid and L-isocitrie id, M 3. Enolase Animal tissues and yeast 2-phosphoglycen'c acid Phospyruvic acid plus H 0,

utases:

1. Glyoxalase Living organisms in general"-.. Methyl gllyoxal and other substituted D lactic acid.

g yoxa Desmolases:

1. Zymohexase (aldolase)-.. All cells Fructose-ldrdlphosphate Dihydroxyacetone phosphoric a id and phosphoglycen'c acid. 2. Carboxylase Plant tissues Pyruvic acid Acetaldehyde and C0 3. fl-Keto carboxylases Animals, bacteria, plants. B-Keto acids. lz-KQtO acids. 4. Amino acid decarboxylases- Plants, animals, bacteria L-ammo acids Amines and C01. 5. Carbonic anhydrase Erythrocytes Carbonic acld C0: H2O. Other enzymes: I

1. Phosphorylase Animal and plant tissues tarch orglycogen and phosphate Glucose-l-phosphate. 2. Phosphohexoisomeraselu se fi-phosphate Fructose-G-phosphate. 3. Hexokinase Adenvsmctl'lphosphate. Ad nosi r iediphosphate plus glucose-6- p osp ate. 4. Phosphoglucomutase Plant and animals lucos -l-ph sphate Glucose-fi-phosphate.

Of the various enzymes, the following table indicates 3, phospholipase C enzymes of particular interest set forth m accordance 3.2 Acting on glycosyl compounds with the I.U.B. classification. 3.2.1 Glycoside hydrolases 1. Oxidoreductases 1. oz-amylase 1.1 Acting on the CH-OH group of donors 40 4. cellulase 1.1.1 With NAD or NADP as acceptor 17. lysozyme 1. alcohol dehydrogenase 23. fl-galactosidase 6. glycerol dehydrogenase 27. amyloglucosidase 2-6. glyoxylate reductasc 31. B-glucuronidase 27. 'L-lactate dehydrogenase 3.4 Acting on peptide bonds 37. malate dehydrogenase 3.4.2 Peptidyl-amino acid hydrolase 49. glucose 6-phosphate dehydrogenase 1. carboxypeptidase A 17. mannitol 1-phosphate dehydrogenase 3.4.4 Pcptidyl-peptide hydrolase 1.1.2 With cytochrome as an acceptor 5. a-chymotrypsin 3. L-lactate dehydrogenase 10. papain 1.1.3 With 0 as acceptor 3.5 Acting on CN bonds other than peptide bonds 4. glucose oxidase 3.5.1 In linear amides 9. galactose oxidase 5. urease 1.2 Acting on the CH-NH; group of donors 3.6 Acting on acid anhydride bonds 1.4.3 With 0 as acceptor 3.6.1 In phosphoryl-containing anhydridcs 2. L-amino acid oxidase 1. inorganic pyrophosphatase 3. D-amino acid oxidase 4. Lyases 1.6 Acting on reduced NAD or NADP as donor 4.1 Carbon-carbon lyases 1.6.99 With other acceptors diaphorase 4.1.2 Aldehyde lyases 1.10 Acting on diphenols and related substances as 7. aldolase donors 4.2 Carbon-oxygen lyases 1.10.3 With 0 as acceptor 4.2.1 Hydrolases 1. polyphenol oxidase 1. carbonic anhydrase 3. ascorbate oxidasc 4.3 Carbon-nitrogen lyases 1.11 Acting on H 0 as acceptor 4.3.1 Ammonia lyases 1.11.1 3. histidase 6. catalase 7. peroxidase Lmkmg Group (X) 3. H ydrolases The ligand or ligand analog is normally bonded either 3.1 Acting on ester bonds 7 directly to the enzyme, by a single or double bond, or 3.1.1 Carboxylic ester hydrolases preferably to a linking group. For those ligands, which 7. cholinesterasc are haptens, and for which the receptors are antibodies 311.3 Phosphoric monoester hydrolases the ligand will have been bound to a protein for the purl. alkaline phosphatase pose of preparing the antibodies. Since the antibodies will 3.1.4 Phosphoric diester hydrolases recognize that portion of the ligand molecule which ex- 31 tends from the protein, ordinarily the same linking group will be attached on the same site on the ligand, as was used in bonding the ligand to the protein to provide the antigenic substance.

The functional groups which will be present in the enzyme for linking are amino (including guanidino), hydroxy, carboxy, and mercapto. In addition, activated aromatic groups or imidazole may also serve as a site for linking.

Amino acids having amino groups available for linking include lysine, arginine, and histidine. Amino acids with free hydroxyl groups include serine, hydroxyproline, tyrosine and threonine. Amino acids which have free carboxyl groups include aspartic acid and glutamic acid. An amino acid which has an available mercapto group is cysteine. Finally, the amino acids which have activated aromatic rings are tyrosine and tryptophan.

In most instances, the preferred linking group will be the amino group. However, there will be situations with certain enzymes, where one of the other linking groups will be preferred.

The ligand, of course, will have great diversity of functionalities which may be present. In addition, as already indicated, the functionalities which are present may be modified so as to form a different functionality, e.g., keto to hydroxy or an olefin to aldehyde or carboxylic acid. To that extent, the choice of groups for linking to the ligand may be varied much more widely than the choice of groups for linking to the enzyme. In both cases, however, a wide variety of different types of functionalities have been developed, specifically for linking various compounds to proteins and particularly enzymes.

Where a linking group is employed for bonding the ligand to the enzyme, it will be the more frequent procedure to bond the linking group to the ligand to provide an active site for bonding to the enzyme. This may be achieved in a single step or may require a plurality of synthetic steps, including blocking and unblocking the active groups on the ligand, other than the one involved in providing the linking group. The linking groups which are reported hereafter are solely concerned with the bridge bonding the enzyme and the ligand.

Where a linking group is used, there will normally be from one atom to 14 atoms in the chain, more usually from two atoms to 8 atoms in the chain bonding the ligand to the enzyme. Where cyclic structures are involved, the cyclic structure will be equated to the number of atoms providing a similar length to the chain.

The linking group (excluding the atoms derived from the ligand and enzyme), when other than a direct bond is involved, will be of from about 1 to 30 atoms-carbon, hydrogen, nitrogen, oxygen, phosphorous, and sulfur more usually 4 to 20 atoms.

Preferably, the linking group will normally be of from zero to 14 carbon atoms, usually from 1 to 8 carbon atoms and from 1 to 8 heteroatoms, and frequently of from 1 to 8 carbon atoms and from 1 to 4 heteroatoms, which are oxygen, sulfur and nitrogen, more usually oxygen and nitrogen. The most frequent heterofunctionalities present in the linking group are nonoxocarbonyl or thiocarbonyl, amino, imino (oxirne or imidate) diazo,

or oxy.

A group of linking groups are derived from a group having a nonoxocarbonyl functionality and when a second functionality is present, the second functionality may be based on a second nonoxocarbonyl functionality, a haloalkyl, O-substituted hydroxylamine, imino, amino or diazo. The linking group will normally have from 2 to 8 carbon atoms and from 1 to 4 heteroatoms which are usually oxygen and nitrogen (the heteroatoms of the ligand and enzyme are not included in the above range of heteroatoms). Such determination is somewhat arbitrary, so that between a carbon atom of the ligand and a carbon atom of the enzyme, there may be as many 32 as six heteroatoms. The heteroatoms may be part of the linking group chain or branched from the chain, e.g., nonoxocarbonyl oxygen.

One group of linking groups will have from 2 to 6 carbon atoms, more usually 2 to 4 carbon atoms and be an aliphatic non-oxo carbonyl functionality. (Another group of linking groups will have from 2 to 8 carbon atoms and have from 1 to 2 heteroatoms, e.g., oxygen and nitrogen, in the chain, such as amino, oximino, diazo, oxy, and the like.

The following tabulation indicates various linking groups, varying with the functionalities present on the ligand and the enzyme. Except as indicated, the linking group satisfies one to two valences on the ligandand enzyme functional groups to which it is bound.

Ligand amino (NH), or hydroxyl Enzyme amino (-NHz), hydroxyl (-0 or mereapto (-SH) (only primary amino) Ligand oxoearbonyl :0)

Enzyme amino (-NHz), hydroxyl (-OH) or mercapto (-SH) Ligand Enzyme amino (-NHz), hy)droxyl (-OH),

O I. non-0x0 carbonyl (C or mercapto (-SH I Z"--arylene of from 6 to 10 carbon atoms.

Where the enzyme is to be linked through a carboxyl group of the ligand or a linking group bonded to the ligand, either esters or amides will be prepared. The ligand may be bonded to any of the linking groups which are appropriate to provide a link between the ligand and the alcohol or amine group of the enzyme to form the ester or amide group respectively. When the enzyme has an activiated aromatic ring, the ligand may be bonded to an aromatic diazonium salt to provide the desired bridge.

The linking group will be selected in accordance with the following considerations. The bonds formed must be stable under the conditions of the assay. When bonding the ligand through the linking group to the enzyme, the enzyme must retain at least a portion of its activity upon isolation, The enzyme must not prevent binding of the ligand to the receptor. The functionalities should permit some selectivity, so that bonding can be directed to specific' groups or types of groups in both the ligands and enzymes.

A few illustrations of how linking groups may be introduced are considered worthwhile. For example, if the ligand has an amino group, the amino may be bonded to form u-bromo-acetamide. This product may then be used to form a carbon nitrogen bond to an amino acid of an enzyme which has a free amine group, e.g., lysine.

If the ligand has a keto group, the carbonyl may be condensed directly with an amine group of the enzyme, or the O-carboxy methyloxime may be prepared with O- carboxymethyl hydroxylamine. A mixed anhydride, with isob'utyl chloroformate is formed, which may then be 34 used to form the carboxamide with the amino group of the lysine.

Where a carboxyl group is present in the ligand, it may be convenient to react the carboxy group to form the monoamide of phenylenediamine. The resulting compound may then be diazotized to form the diazo salt which may be coupled with tyrosine present in the enzyme.

Another way to form the linking group would be to have an alcohol of a ligand react with succinic anhydride to form the monoester. The free carboxy group can then be activated by preparing the mixed anhydride and be used for reaction with an amine in the enzyme.

With an amino group present on the ligand, this may be reacted with maleic anhydride under forcing conditions to prepare the maleimide. The maleimide may then be combined with cysteine in the enzyme to provide by a Michaels addition the 3-thiosuccinimide.

For poly-functionalized ligands such as proteins it will usually be necessary to use special techniques to prevent the formation of enzymes coupled together which are then bonded to the ligand. Having the two or more enzymes coupled would made inhibition difiicult. Techniques can be employed where one group of a bifunctional reagent can be made unreactive, while the other group reacts with the enzyme or protein ligand. The other group can then be activated to carry out the second stage of linking the protein ligand to an enzyme.

Various bifunctional reagents can be employed. For example, a functionalized diazosulfonate can be used. One of the proteins can be bonded to the functionality and then the modified protein added to the other protein and the diazosulfonate group activated with the light.

While for the most part, the enzyme may be bonded to any convenient position of the ligand, either through a functionality naturally present in the ligand or one introduced synthetically, there are preferred methods of bonding the enzyme to the ligand. First, it should be recognized that the ligand of the enzyme-bound-ligand need not have any biological activity. One is primarily concerned in not disturbing the geometry and polar site relationships of a substantial portion of the ligand molecule. Where the ligand is a hapten, the enzyme will therefore normally be bonded at the same site as was employed for attachment to the protein in the preparation of the antigen. Where the ligand is an intact antigen, several sites may be employed for attachment to one or more enzyme molecules with the obvious limitation that the number of enzyme molecules must not be so great as to prevent binding to the antibody. Where the ligand has a natural receptor other than an antibody, the point(s) of attachment will also be determined primarily by the necessity to preserve strong binding to the receptor.

Furthermore, if one is attempting to assay one of a variety of molecules which are quite similar, for example steroids, but differing in their substituents at the 17 position, one would choose to mark the molecule with the enzyme at a site distant from the distinguishing functionality. Following the steroid analogy, it would frequently be preferable to bond at the 3 position, rather than at the 17 position, since the distinctive portion of the molecule is usually at the 17 position. For the most part, the 3 position is either an alcohol or a ketone, the ketone normally being associated with aliphatic unsaturation. Also, the 6 position is a useful site.

The same or similar consideration will be present with other ligands. For example, with a polypeptide, which has a natural receptor site, one would preferably bond away from the receptor site.

The number of ligands which may be bonded to the enzyme will be limited by the number of available sites for bonding to the enzyme. In most cases this will be the amino groups which are present, but as already indicated, carboxyl, hydroxyl, thiol and activated aromatic rings, e.g., phenolic, are also useful sites.

Various factors will affect the number of ligands which is optimum for a specific enzyme and a specific ligand. Of prime consideration is the number required for obtaining the desired degree of inactivation when receptor is bound to the enzyme-bound-ligand. The number required will vary with the mode of attachment and the conditions for attachment of the ligand to the enzyme. Except under special circumstances, e.g., afiinity labelling, there will usually be differences in degree of inactivation, as to each site to which the receptor is bound to the enzyme through a ligand. In addition, there may be cumulative effects, with an increase in the number of receptors bound to the enzyme through ligand.

Other considerations as to the number of ligands per enzyme will be the effect of the increasing number of ligands on: solubility of the enzyme-bound-ligand; activity of the enzyme-bound-ligand in the absence of receptor; and the sensitivity of the assay. Therefore, the choice of the number of ligands bonded to the enzyme is usually empirically determined, based on the effect of varying the number of ligands on the enzyme has on the assay.

With small enzymes, e.g., lysozyme, those that have molecular weights in the range of 10,000 to 30,000 from 2 to ligands can be sufficient. With larger enzymes, e.g., malate dehydrogenase, of molecular weight in the range of 30,000 to 150,000, 2 to 30 ligands can be sufficient. For malate dehydrogenase 2 to 22 ligands on the average will be employed. As few ligands as possible should be bonded to the enzyme to achieve the desired degree of inhibition. Desirably, the number of ligands per enzyme should be in the range of 1 to 20, more preferably 1 to 12.

As already indicated, because of the diversity of enzymes which can be used for the assay and the variety of functionalities in the enzyme available for attachment, and the varying activities of the functionalities for being bonded to the ligand as well as their relative position to the active site of the enzymes, different numbers of ligands will be necessary for obtaining the desired degree of inhibition, when the enzyme-bound-ligand is bonded to antibody. Furthermore, the desired degree of inhibition may vary, depending on the sensitivity required for an assay for a particular ligand.

It is found, for the most part, that increasing the average number of ligands increases the amount of inhibition, up to a degree of substitution, where further substitution does not provide a significant increase in inhibition. Therefore, by varying the conditions for the reaction between the modified ligand (ligand and linking group) and the enzyme, varying degrees of substitution can be achieved. The time for the reaction, the mole ratio of ligand to enzyme and the like can be varied. Also, the reactive functionality on the linking group can be varied to change the number and sites for substitution. One can then empirically determine the number of ligands required for the desired degree of inhibition.

It should also be noted that in referring to inhibition of an enzyme, the substrate for the enzyme plays a role. Different degrees of inhibition may be achieved with different substrates. Thus, not only can one obtain varying degrees of inhibition by varying the number of ligands bonded to the enzyme, and the sites to which the ligands are bonded, but also, with some enzymes, by varying the substrate for the enzyme.

It is also found that with increasing substitution of the enzyme by ligand, there can be reduction in enzyme activity. The turnover number diminishes and there is a concomitant increase in the Michaelis constant. The decrease in turnover number with increasing substitution will vary with the enzyme. By employing enzymes which have a high initial activity, a loss of as much as seventy-five percent of initial activity can be tolerated.

(Turnover number is the number of substrate molecules transformed per unit time per enzyme molecule. Lehninger, Biochemistry, Worth Publishers, New York, 1970. Since the turnover number is reported at varying temperatures and on varying bases, e.g., weight of protein as an indication of number of enzymes or change in a spectrophotometric value as an indication of number of substrate molecules, there is at the present no simple comparison between the turnover number of different enzymes. Therefore, no minimum numerical turnover number for preferred enzymes can be given.)

Also, the ligand will be attached to the enzyme by a relatively short chain, usually of the order of 1.5 to about 20 A. more usually about 3 to 10 A.

Enzyme Assay Receptor In the subject invention, for the most part, the receptors will be macromolecules which have sites which recognize specific structures. The recognition of the specific structures will be based on Van der Waals forces, which provide a specific spatial environment which maximizes the Van der Waals forces; dipole interactions, either by permanent or induced dipoles; hydrogen and ionic bonding; coordinate covalent bonding; and hydrophobic bonding. For a detailed discussion of mechanisms by which receptors bind ligands, see Goldstein, et al., Principles of Drug Action, Harper and Rowe, New York, 1968. Y

The macromolecules of greatest interest are proteins and nucleic acids which are found in cell membranes, blood, and other biological fluids. These compounds include en zymes, antibodies, ribonucleic acid (RNA) and deoxyribonucleic acid (DNA) and natural receptors.

The most convenient group of proteins for use in the subject invention are antibodies. These materials are con-" veniently used in the analysis of the category of ligands referred to as haptens. Antibodies are produced by introducing an immunogenic substance into the bloodstream of a living animal. The response to the introduction of the immunogenic substance for antigen is the production of antibodies which act to coat the antigen and detoxify it or precipitate it from solution. The protein forms a coat which is geometrically arranged so as to have the antigen fit the spatial arrangement of the protein. This maybe analogised to a lock and key. The interaction is normally reversible, in that the antigen is subject to displacement or removal by various means without destruction of the rcceptor site.

There are many materials which are antigens and will produce an immunogenic response by being introduced into the bloodstream of a vertebrate. However, a number" of materials of interest are not antigens, but are haptens,

and in that situation, an extra step in preparing the anti body is required. This method of preparing antibodies with materials other than antigens is well known and may be found in Microbiology, Hoeber Medical Division, Harper and Rowe, 1969. See also, Landsteiner, Specificity of Serological Reactions, Dover Publications, N.Y. 1962; Kabat, et al., Experimental Immunochemistry, Charles C.; Thomas, Springfield, Illinois, 1967; and Williams, et al.,

Methods in Immunology and Immunochemistry, Vol. 1,2"

Academic Press, New York, 1967. r The material which isto be assayed is bonded to protein by any convenient means and the modified protein introduced into the blood stream. The same type of bonding groups used with the enzyme attachment to the ligand may be employed. The antibodies which form will 37' include groupsof antibodies which are shaped to fit the foreign moiety bonded to the protein. Therefore, antibodies are obtained which are specific to the compound or moiety bonded t o'the protein. By careful separation techniques, the antibodies primarily concerned with the 38 pounds of biological interest. Compounds for which receptors are naturally occurring include thyroxine, corticosterone, cortisone, ll-desoxycortisol, ll-hydroxyprogesterone, estrogen, insulin and angiotensin. See, for example, Vonderhaar et al., Biochem. Biophysics Acta.,

5 molety m question, can be concentrated so as to provide 176, 626 (1969). All of these ligands have been studied an antibody composition which is primarily related to the and reported upon in the literature in connection with specific moiety which was bonded to the protein. studies on their binding with specific receptors.

TABLE I Ligand Receptor for ligand reference Ligand structure Thyroxin Thyroxin Binding Globulin (TBG) Thyroxin Binding I I Prealbum (TBA) B.E.P. Murphy, 0. J. .T. Pattee, J. Clin. NH:

Endocn, 24, 187 (1964).

HO- -O -CHz-CH-COOH I Thyroxine Cortieosterone Protein from Brain Cell Nuclei, B. McEwen, L. Plapinger CHzOH Nat. 266, 263 (1970). I

I C=O Corticosterone Cortisol (R=O H, B.E. Murphy, J; Clin. Endocn, 28, 343 (1968), 27, 973 1967) CHzOH Cortisone (R=O) Corticosteroid Binding Globulin (Transcortin). I lkdefixgprtisol 0: T, CHaI Cortisone Estradiol Receptor Site for Estrogen From Uterus, BBA, 176, 626 (1969)- CH '7 i CH 3 U Estradiol Insulin QR. Morgan, W. M. Holland, III Diabetes, 1966 See below} Angiotensin II L.B. Page, E. aber, A.Y. Kimura, A. Peruode, J. 01112. End. See below.

N H; S S NH: N H: N Hg I 1 H-Gly-Ile-V -Glu-Glu-Cys-Cys-Ala-Ser-Val-Cys-Ser-Leu-Tyr-Glu-Leu-Glu-Asp-Tyr-Cys-Asp-OH H-Phe val-Asp-Glu-His-Leu-cys-Gly-S er-His-Leu-Val-G lu-Ala-L eu-T yr-Leu-Val-Cys-Gly-Glu-Ar -G1y-Phe-Phe-Tyr-Thr-Pro-Lys-Ala-0H.

NH: NH: 2 Asp-Arg-Val-Tyr-Ileu-His-Pro-Phe.

To illustrate this method, para-aminobenzene arsonate is diazotized to form the diazo salt. By combining the diazo'salt with rabbit globulin, the rabbit globulin may be labeled with pafa-azobenzene arsonate. By introducing this composition into the blood stream of an animal other than-'a"rabbit, for example, a sheep, antibodies can be formed which will' have a spatial arrangement which accept's solely the a'zobenzene arsonate.

Inaddition to antibodies, there are a number of naturally 'occurringr'e'ceptors which are specific to com- 75 type to evaluate a wide variety of enzymes when bonded to a carboxyl group by means of a mixed anhydride. The information thus obtained can be readily extrapolated to what one would expect from bonding other similar drugs in an analogous manner to the same enzyme.

Experimental The following examples are olfered by way of illustration and not by way of limitation.

(All temperatures are recorded in centigrade.)

INDEX gentle o dcaigboxymethyl morphine conjugate to glyoxylate rec as u e- Ofl-(wisopropyl) carboxymethyl morphine conjugate to malate dehydr e 46 1.9 -carboxymethyl morphine conjugate to glucose 6-phosphate dehydrogenase 47 1.10 0 -imid0ylmethyl morphine conjugate to lysozyme 47 1.11 O -imidoylmethyl morphine conjugate to glucose (i-phosphate dehydr g e 47 2. Methadone: 2.1 6-keto-7,7,-diphenyl-B-dimethylaminodecanoie acid conjugate to lysozyme 48 3. Meperidine: 3.1 4-carbeth0 -1-carboxymethyl-4-phenylpiperidine conjugate to lysozyme 48 4. Amphetamine: 4.1 N-carboxymethyl amphetamine con ugate to lysozyrne- 49 5. Barbiturates:

5.1 N -carboxyrnethyl phenobarbital conjugate to lysozyme- 50 5.2 -(7-C10t011i0 acid)-5-(2-penty1)-barbituric acid conjugate to lysozy-me 51 5.3 N-canboxymethyl glutethimide 52 5.4 N-( i-carboxybutyl) phenobarbital conjugate to lysozyme 52 5.5 5-(vcrotonic acid)-5-(2-pentyl) barbiturie acid conjugate to lysozyme 53 6. Cocaine:

6.1 Ecgonine conjugate to lysozyme 54 6.2 p-Diazobenzoyl ecgonine con ugate to lysozyme 54 7. Insulin: 7.1 p-Diazobenzamide modified insulin conjug malate dehyd mgenqse 55 8. bteroids:

8.1 Testosterone-3-carboxymethyloxime conjugate to malate dehydr g e 55 8.2 3-(O-carboxymethyl) estradiol conjugate to malate dehydr n 56 EXAMPLE A Preparation of morphine antibodies and binding to support 1. Morphine (900 mg.) was dried for 4 hours at 50 C., 0.01 mm. Hg. The dried morphine was dissolved in 18 ml. of abs. ethanol and 125 mg. sodium hydroxide was added, followed by the addition of 350 mg. dry sodium chlorostirred and refluxed for four hours. The hot solution was treated with 3.8 ml. ethanolic hydrogen chloride (0.85 M) and then filtered while still warm. On cooling overnight, a precipitate (272 mg.) formed which was collected and recrystallized from ethanol/water. On addition of ether to the original filtrate an additional precipitate was obtained which was also recrystallized from ethanol/water. Total yield 600 mg. (55%). On heating this product to 75 C. in vacuo there was a weight loss corresponding to 0.48 molecule of ethanol or 1.15 molecule of water. The dried compound decomposes at 190-220 (depends on rate of heating).

Anal: S H NO Percent theor.: C, 66.45; H, 6.16;

N, 4.08. Percent found: C, 65.87; H, 6.98; N, 4.09, 4.07.

NMR(C5D5N) 2.44 p.p.m. (CH3), 5.08 p.p.m.

2. Carboxymethyl morphine .(240 mg.) suspended in 8 ml. dry dimethyl foramide (DMF) was cooled to -15? ,C. and treated with 84 l isobutyl chloroformate.

The solid dissolved while stirring for 30 minutes at is about 4.0 ml. per rabbit.

ate was added to this solution and the mixture was kept at 0 C. overnight. It was then dialyzed againstdistilled water with four changesv of Water (dialysis 1:.80 lyophilized to give 350 mg. of conjugate.

Hapten concentration on the protein: 7

MWCMM=327 B =41600 M MWBsA=64,4OO js,e. M= 107 o.

and

The ultraviolet spectrum was measured at 280 nm. in

a 1 cm. cell; d=0.59 when the concentration was 0.287

mined from the above data and the formula: a

=C M BsA) XMWc1 1 MWBSA where X number of haptens per molecule, W weight of protein conjugate per liter and MW is the molecular g./l. in water. The degree 'of conjugation can be deter weight where CMM refers to the hapten carboxymethylmorphine, and BSA refers to the protein.

X 46.6 haptens/molecule 3. Antisera may be obtained as follows: The antigen (hapten coupled to an appropriate protein, see above example) is made up in a saline solution (9 g./liter) at a 2 mg./ml. concentration. Per 1.0 ml. aliquot of the above solution, introduced, there is introduced simultaneously 2 ml. of Complete Freunds Adjuvant in homogenized form by means of a two-way needle. For subcutaneous injections, approximately 0.3 ml. (antigen+Freuds solution) is injected per site and for intraperitoneal injections, approximately 0.4 ml. is

tion is added to the serum dropwise with stirring at 4 C.

After standing for 1 hour at that temperature, the solution is centrifuged at 10,000 r.p.m. for 15 minutes and the supernatant removed. The residue is suspended in as small a volume as possible of 1x BB (borate buffer, see below for description), transferred to a dialysis bag and dialyzed overnight against BB, pH 8.0 The residue in the dialyzed bag is then isolated and frozen.

(To made borate buffer, dissolve 24.6 g. boric acid in water, adjust the pH with sodium hydroxide to a pH 7.98.0, add 0.1 g. of sodium azide and 0.01 g. of ethylmercurithiosalicylate and bring the'total volume to o'ne '2 liter.

4. Into 20 ml. of dimethyl formamide is introduced 400 mg. aminoethyl-Bio-Gel P-300 and 300 mg. of carboxymethyl morphine (see Example A-1) and 1 g. 'sodium bicarbonate is added. After stirring the suspension for two days at 4 C., the suspension is filtered, the residue is washed with water until the washings are neutral, and then the residue is dried in vacuuml i I The resulting product is then suspended-in. 20 ml. rabbit serum containing morphine antibodies and is stirred for 4 hours at 4 C. Filtration gives a residue which is resuspended in -5 ml. 'phthalate butter, pH 3.8..:(0.1 M)

of substantially pure antibodies.

5. Into a flask were cornbined 5 m1. Sepharose ZBSUS-Q pension, 5 ml. water, and 5 ml. mg./ml. vCNBr 80111-9 tion and the pH adjusted to 11.5 with 4N NaOH. While stirring the mixture, the pH was metered and maintained at 11-11.5 with 4 N NaOH until no further change in pH.

injected. The total dosage

Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US3878187 *11 Sep 197215 Apr 1975Syva CoPolypeptide derivatives of amphetamine and analogs for immunoassays
US3879262 *1 May 197322 Apr 1975Akzona IncDetection and determination of haptens
US3932221 *9 Jun 197213 Jan 1976Merck Patent Gesellschaft Mit Beschrankter HaftungImmunological isozyme determination method
US3959078 *18 May 197325 May 1976Midwest Research InstituteEnzyme immobilization with a thermochemical-photochemical bifunctional agent
US4012285 *27 Nov 197315 Mar 1977Merck Patent Gesellschaft Mit Beschrankter HaftungAnalysis of isoenzyme patterns
US4025501 *20 Mar 197524 May 1977Syva CompanyPolypeptide propoxyphene derivatives for immunoassay reagents
US4043872 *29 Dec 197523 Aug 1977Syva CompanyPolyiodothyronine immunoassay
US4069105 *3 Mar 197717 Jan 1978Syva CompanyLidocaine antigens and antibodies
US4134792 *6 Dec 197616 Jan 1979Miles Laboratories, Inc.Specific binding assay with an enzyme modulator as a labeling substance
US4168207 *3 Aug 197718 Sep 1979Syva CompanyTBG assay
US4171244 *17 Mar 197716 Oct 1979Syva CompanyEnzyme-bound-polyidothyronine
US4230797 *10 Apr 197828 Oct 1980Miles Laboratories, Inc.Nucleotide
US4233401 *14 Jul 197711 Nov 1980Syva CompanyAntienzyme homogeneous competitive binding assay
US4233402 *5 Apr 197811 Nov 1980Syva CompanyReagents and method employing channeling
US4234681 *21 Jul 197818 Nov 1980The Regents Of The University Of CaliforniaImmobolized light emitting systems
US4235969 *8 May 197825 Nov 1980Syva CompanyImmunoassays for determination of benzamides of n,n-dialkylethyleneamines
US4239745 *22 Nov 197816 Dec 1980Penicillin Assays, Inc.Incubation with tagged antibiotic and antibiotic sensitive cells
US4239852 *12 Jun 197816 Dec 1980Penicillin Assays, Inc.Antibiotic detection method
US4241177 *28 Aug 197823 Dec 1980Syva CompanyPropanolol antigen conjugates and antibodies
US4244939 *12 Jun 197813 Jan 1981Baxter Travenol Laboratories, Inc.Barbituric acid tracers and their preparation
US4250253 *9 Mar 197810 Feb 1981Snamprogetti S.P.A.Carbonic anhydrase complexing
US4255329 *2 Apr 197910 Mar 1981Syva CompanyDouble receptor fluorescent immunoassay
US4287300 *26 Jul 19791 Sep 1981Syva CompanyCharge effects in enzyme immunoassays
US4318980 *15 Oct 19799 Mar 1982Miles Laboratories, Inc.Heterogenous specific binding assay employing a cycling reactant as label
US4347312 *20 Mar 198031 Aug 1982Research Triangle InstituteColorimetric and quantitative analysis using an enzyme-labelled antibiotic and an immobilized antibody; penicillins
US4372745 *10 Feb 19818 Feb 1983Electro-Nucleonics, Inc.Chemical luminescence amplification substrate system for immunochemistry involving microencapsulated fluorescer
US4375414 *21 Jan 19771 Mar 1983Meir StrahilevitzImmunological methods for removing species from the blood circulatory system and devices therefor
US4378428 *30 Mar 198129 Mar 1983Baker Instruments CorporationMethod for carrying out non-isotopic immunoassays, labeled analytes and kits for use in such assays
US4378458 *30 Mar 198129 Mar 1983Baker Instruments CorporationA 3-furyl phosphate derivative having a nucleotide base substituent in the 2 position
US4446233 *5 May 19821 May 1984E. I. Du Pont De Nemours And CompanyHomogeneous immunoassay using covalent hybrid antibodies
US4472301 *27 May 198218 Sep 1984Miles Laboratories, Inc.Propranolol immunogen and antibodies
US4474878 *29 Sep 19752 Oct 1984Cordis Laboratories, Inc.Sandwich EIA for antigen associated with hepatitis
US4477576 *26 Jul 198216 Oct 1984Mex Research AssociatesQualitative analysis; solid matrix linked to protein-antigen-antibody-enzyme
US4489156 *23 Apr 198118 Dec 1984Syva CompanyAntigen conjugates
US4489157 *28 Sep 198118 Dec 1984Syva CompanyChloramphenicol derivatives
US4492751 *15 Oct 19798 Jan 1985Miles Laboratories, Inc.Heterogenous specific binding assay employing an enzyme substrate as label
US4495281 *21 Oct 198222 Jan 1985Miles Laboratories, Inc.Contains dibenzo(a,d)cycloheptene; dibenz!b,f) azepine and dibenz(b,e)oxepin rings
US4550075 *22 Jun 198329 Oct 1985Kallestad Laboratories, Inc.Intermixing fluid medium with labeled avidin conjugated compound reacting with pyruvate carboxylase
US4560648 *23 Sep 198324 Dec 1985Syntex (U.S.A.) Inc.Homogeneous enzyme immunoassay for ferritin
US4587212 *18 May 19836 May 1986Boots-Celltech Diagnostics LimitedEnzymes, measurement, milk, steroids
US4604365 *28 May 19825 Aug 1986Electro-Nucleonics, Inc.Immunoprecipitation assay
US4606855 *22 Jul 198319 Aug 1986Mex Research Associates C/O Leon ReimerBioassay
US4608252 *27 Sep 198526 Aug 1986Syntex (U.S.A.) Inc.Chloramphenicol derivatives antigens and antibodies
US4614712 *25 Feb 198330 Sep 1986The Upjohn CompanyImmunoassays with luciferase labeled ligands or receptors
US4629688 *10 Apr 197816 Dec 1986Miles Laboratories, Inc.Homogeneous specific binding assay method
US4642285 *2 May 198410 Feb 1987Diamedix CorporationEnzyme-immunoassay
US4654311 *15 Jun 198431 Mar 1987Syntex (U.S.A.) Inc.Serum pretreatment for digoxin assay
US4708929 *8 Apr 198524 Nov 1987Microgenics CorporationMethods for protein binding enzyme complementation assays
US4716109 *30 Jan 198429 Dec 1987Boots-Celltech Diagnostics LimitedEnzyme inhibitor label
US4719176 *31 Oct 198312 Jan 1988Klotz Irving MEnzyme-free diagnostic binding reagents
US4721704 *9 May 198626 Jan 1988Peninsula Laboratories, Inc.Potent synthetic atrial peptide analogs
US4780409 *28 Apr 198625 Oct 1988Genetic Systems CorporationSpecific binding with temperature-sensitive polymer
US4785080 *29 Aug 198515 Nov 1988Baker Instruments CorporationLabeled analytes
US4791055 *9 Jan 198613 Dec 1988Miles Inc.Enzyme-cleavable bonds
US4791068 *22 Jun 198413 Dec 1988Scripps Clinic And Research FoundationDiagnostic assay for inhibitor of tissue-type and urokinase-type plasminogen activators
US4813924 *8 Mar 198521 Mar 1989Meir StrahilevitzDrugs, haptens, antigens, antibodies
US4830786 *27 Feb 198616 May 1989Syntex (U.S.A.) Inc.Condensation product of squaric acid with compounds such as aniline
US4847195 *24 Nov 198711 Jul 1989Syntex (U.S.A.) Inc.Glucose-6-phosphate dehydrogenase conjugates useful in polyiodothyronine assays
US4868132 *3 Feb 198719 Sep 1989Abbott LaboratoriesFluorescence polarization immunoassay for amphetamine/methamphetamine
US4888276 *26 Jun 198619 Dec 1989Minnesota Mining And Manufacturing CompanyMethod and composition for the diagnosis of Lyme disease
US4889800 *21 Aug 198726 Dec 1989Scripps Clinic And Research FoundationSynthetic polypeptides and receptor molecules derived therefrom and methods of use
US4946958 *26 Sep 19887 Aug 1990The Welsh National School Of MedicineChemiluminescent acridinium labelling compounds
US5057430 *15 Sep 198815 Oct 1991Biotronic Systems CorporationMeasurement of bubbles released by reaction of enzyme bound to substrate and analyte indicates concentration
US5073629 *23 Jan 198917 Dec 1991Abbott LaboratoriesHaptens attached to immunogenic carrier; quantitative analysis , drugs testing
US5089388 *21 Feb 198618 Feb 1992Syntex (U.S.A.) Inc.Antibodies for salicylate and their preparation
US5101015 *10 Apr 198931 Mar 1992Abbott LaboratoriesNitrogen-functional-group-containing immunogen
US5103021 *30 Jul 19877 Apr 1992Syntex (U.S.A.) Inc.Acetaminophen analogs, antigens, and antibodies
US5143852 *14 Sep 19901 Sep 1992Biosite Diagnostics, Inc.Quantitative analysis
US5248791 *14 Jan 199228 Sep 1993Abbott LaboratoriesReagents, methods and kits for an amphetamine-class fluorescence polarization immunoassay
US5260441 *28 Feb 19899 Nov 1993Abbott LaboratoriesFluorescence polarization process for detecting unauthorized consumption of morphine
US5273885 *31 Jul 199228 Dec 1993Syntex (U.S.A.) Inc.Conjugates of monophenyl thyroid analogs useful in assays
US5279937 *30 Apr 199218 Jan 1994Detechnology CanadaUse of macroglobulins to improve the signal-to-background ratio in affinity binding assays
US5328828 *20 Jul 199212 Jul 1994Syntex (U.S.A.) Inc.Immunoassay for amphetamines with antibodies for conjugation and enzymes
US5329019 *27 Apr 199212 Jul 1994Syntex (U.S.A.) Inc.Squaraine dye compounds
US5334513 *3 Sep 19922 Aug 1994Syntex (U.S.A.) Inc.Measuring migration distance between zones
US5354693 *29 Jun 199311 Oct 1994Abbott LaboratoriesReagents, methods and kits for an amphetamine-class fluorescence polarization immunoassy
US5358690 *30 Dec 199125 Oct 1994Lamina, Ltd.Used to perform diagnostic test for pathogenic organisms, detection and identification of toxin and drug contamination in food for human and animal consumption, monitoring pesticide residues in water, soil and food
US5358931 *15 Jan 199325 Oct 1994The Regents Of The University Of CaliforniaInteraction of thermal hysteresis proteins with cells and cell membranes and associated applications
US5416214 *29 Mar 199416 May 1995Syntex (U.S.A.) Inc.Use in fluorescent assay
US5434052 *21 Jul 199318 Jul 1995Microgenics CorporationComplementation assay for drug screening
US5451507 *10 May 199419 Sep 1995Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5468647 *1 Sep 199421 Nov 1995Syntex (U.S.A.) Inc.Method for immunochromatographic analysis
US5516639 *22 Jul 199314 May 1996Mayo Foundation For Medical Education And ResearchAntibodies specific for human prostate glandular kallkrein
US5516647 *5 Nov 199314 May 1996Abbott Laboratories6-phenyl-imidazo(2,1-b)thiazoles
US5518890 *20 Nov 199221 May 1996Mccormick & Company, Inc.Insect parts; immobilized chitinase
US5527686 *29 Jul 199218 Jun 1996Serex, Inc.Differential binding affinities and dissociation assays based thereon
US5532138 *21 Jun 19942 Jul 1996Behringwerke AgMethod and kits for determining peroxidatively active catalysts
US5605800 *6 Jun 199525 Feb 1997Institut PasteurEnzyme-nucleic acid complex
US5624809 *5 May 199529 Apr 1997Behringwerke AgDevice for immunochromatographic analysis
US5639624 *27 Jun 199417 Jun 1997Board Of Regents Of The University Of NebraskaMonoclonal antibodies specific for metallic cations and method therefor
US5643732 *5 Jun 19951 Jul 1997Strahilevitz; MeirImmunological assay methods
US5677132 *5 Jun 199514 Oct 1997Strahilevitz; MeirUsing antibody; immunoassay of psychoactive drug
US5679526 *1 Aug 199421 Oct 1997Biosite Diagnostics IncorporatedThreshold ligand-receptor assay
US5684144 *7 Feb 19944 Nov 1997University Of North TexasEscherichia coli csrA gene, protein encoded thereby, and methods of use thereof
US5710009 *22 Jun 199520 Jan 1998Serex, Inc.Receptor:release ligand (reland) complexes and release assays using said reland and methods and kits based thereon
US5726023 *6 Jun 199510 Mar 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5731148 *7 Jun 199524 Mar 1998Gen-Probe IncorporatedAdduct protection assay
US5801005 *31 Mar 19951 Sep 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5807695 *27 Dec 199615 Sep 1998Board Of Regents Of University Of NebraskaMetallic cation binding polypeptides and methods therefor
US5808074 *31 Jan 199715 Sep 1998Georgetown UniversityBenzoylecgonine conjugate diagnostic reagents
US5840588 *5 Jun 199524 Nov 1998Strahilevitz; MeirBinding hapten to erythrocyte or latex particles; mixing sample with antibody against hapten, combining antibody with bound hapten; agglutination occurs only when lack of hapten in sample; simplicity, high speed, specificity
US5843634 *4 Jun 19961 Dec 1998Abbott LaboratoriesGenetically engineered enzymes and their conjugates for diagnostic assays
US5846538 *7 Jun 19958 Dec 1998University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the her-2/neu oncogene is associated
US5856083 *3 Nov 19955 Jan 1999Pharmacopeia, Inc.Monitoring a photometric change
US5869445 *1 Apr 19969 Feb 1999University Of WashingtonMethods for eliciting or enhancing reactivity to HER-2/neu protein
US5876712 *6 Jun 19952 Mar 1999University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US5876928 *6 Jun 19952 Mar 1999Institut PasteurMethod of detecting and characterizing a nucleic acid or a sequence of the latter, and enzymatic reactant for the application of this method
US5879894 *19 Sep 19949 Mar 1999Chiron Diagnostics CorporationDetection and/or quantitation of at least two substances in a test sample; application in clinical diagnostics
US5882644 *22 Mar 199616 Mar 1999Protein Design Labs, Inc.Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US5929049 *8 Aug 199727 Jul 1999Dade Behring Marburg GmbhCompound formed by modifying polysaccharide such as dextran and reacting with polypeptide such as avidin, protein a, protein g
US5939272 *11 Jun 199717 Aug 1999Biosite Diagnostics IncorporatedNon-competitive threshold ligand-receptor assays
US5955262 *8 Sep 199221 Sep 1999Institut PasteurEnzyme coupled hybridization probe for rapid and efficient detection of nucleotide sequence in sample
US6013471 *17 Dec 199611 Jan 2000Hybritech IncorporatedDNA encoding hK2 variant polypeptides
US6033890 *22 May 19957 Mar 2000Behring Diagnostics GmbhHomogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
US6060260 *27 Feb 19989 May 2000Dade Behring Inc.Methods for reducing adsorption in an assay
US6075122 *6 Jun 199513 Jun 2000University Of WashingtonA peptide for the detection, monitoring, and treatment of cancer in animals; anticarciongenic agents
US6090567 *22 May 199518 Jul 2000Behringwerke AgHomogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
US6093796 *17 Dec 199625 Jul 2000Mayo Foundation For Medical Education And ResearchRecombinant hK2 polypeptide
US6093809 *6 May 199725 Jul 2000University Technology CorporationNucleotide sequence; anticarcinogenic and antiaging agents; diagnostic applications; evolutionary (e.g., phylogenetic) investigations
US6103237 *26 Mar 199615 Aug 2000Hybritech IncorporatedMore stable to purification than wild type mature hk2 polypeptide.
US6127338 *1 Apr 19983 Oct 2000Calyx Therapeutics, Inc.Three peptides of given amino acid sequences with antihyperglycemic activity; extracts of the fruit momordica charantia
US6129917 *21 Mar 199710 Oct 2000The University Of Georgia Research Foundation, Inc.Immunogenic compositions comprising porphyromonas gingivalis proteins and/or peptides and methods
US6153442 *20 May 199828 Nov 2000Dade Behring Inc.Compounds comprise two biotinyl radicals connected by a chain of atoms; the bis-biotin is conjugated to a member of a specific binding pair; for use in an assay for an analyte
US6159698 *17 Jul 199712 Dec 2000Dade Behring Marburg GmbhReagents for assays for mycophenolic acid
US617180117 Jul 19979 Jan 2001Dade Behring Marburg GmbhMethods for releasing a ligand from a complex
US618041130 Jul 199830 Jan 2001The Regents Of The University Of CaliforniaChromophore incorporating a photolabile group capable of undergoing an irreversible and detectable intramolecular transformation; chromophore is linked to binding site for analyte; for intracelluar analysis
US61875634 Aug 199913 Feb 2001Yale UniversityβIV-spectrin-polypeptides and nucleic acids encoding same
US620715322 May 199727 Mar 2001Viventia Biotech, Inc.Antigen binding polypeptide
US62285757 Feb 19978 May 2001Affymetrix, Inc.Classification of exogenous nucleotide seqences; mixing oligonucleotide probes and sample, analyze hybridization pattern and classify nucleotide sequences in sample
US62286389 Jul 19988 May 2001University Of North Texas, Health Science Center At Fort WorthNucleotide sequence of rna which binds to and antagonizes ability of csra to down-regulate production of certain metabolic products; for altering expression of desired compounds in bulk bacterial cultures
US623548619 Jun 199822 May 2001Mayo Foundation For Medical Education & ResearchScreening humans for mammary gland tumors; incubate antibody and preferential polypeptide, monitor sample for the presence of antibody/polypeptide complexes
US62618369 May 199717 Jul 2001Geron CorporationTelomerase
US626226518 Jun 199917 Jul 2001Microgenics CorporationNon-hydrolyzable analogs of heroin metabolites suitable for use in immunoassay
US629706011 Feb 19992 Oct 2001Biosite Diagnostics, Inc.Assay devices comprising a porous capture membrane in fluid-withdrawing contact with a nonabsorbent capillary network
US630332529 May 199816 Oct 2001Dade Behring Inc.Method for detecting analytes
US630334424 Jun 199916 Oct 2001Maxygen, Inc.Methods and compositions for polypeptide engineering
US631290110 Sep 19996 Nov 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US631971325 Jun 199920 Nov 2001Maxygen, Inc.Methods and compositions for polypeptide engineering
US632613623 Dec 19944 Dec 2001Digene CorporationNucleic acid hybridization probes and immunological probes useful as research and diagnostic tools
US63312753 Aug 200018 Dec 2001Burstein Technologies, Inc.Spatially addressable, cleavable reflective signal elements, assay device and method
US633516018 Dec 19961 Jan 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US634234921 Jul 199829 Jan 2002Burstein Technologies, Inc.A solid support substrate containing a cleavable signal element, a signal responsive moiety and a cleavable spacer; analytes bind the signal element, anchoring the responsive moiety to the element substrate-attaching end after cleavage
US635548424 Jun 199912 Mar 2002Maxygen, Inc.Methods and compositions for polypeptides engineering
US639185431 Jul 200021 May 2002Calyx Therapeutics, Inc.Water soluble hypoglycemic agents
US63919807 Jun 199521 May 2002Aventis Pharmaceuticals Products, Inc.Activated and conjugated polystyrene substrate
US64038076 Jul 200011 Jun 2002Surromed, Inc.Bridged fluorescent dyes, their preparation and their use in assays
US640685522 Nov 200018 Jun 2002Maxygen, Inc.Detection of cytokines and nucleic acid subsequences of polynucleotides and injections
US641068713 Apr 199925 Jun 2002The Regents Of The University Of CaliforniaPolypeptide; for use as antiproliferative agents
US641415224 Oct 19942 Jul 2002University Of Wales College Of Medicine Of Heath ParkLuminescent labelling material and procedures
US642930428 Nov 20006 Aug 2002The Regents Of The University Of CaliforniaScreening for agents that modulate microtubule depolymerization
US643315524 Sep 199713 Aug 2002Tanox, Inc.Isolated cdna or rna polynucleotide comprising nucleic acid sequence encoding polypeptide comprising specified amino acid sequence, or fragment thereof
US645525327 Apr 200024 Sep 2002Maxygen, Inc.Methods and compositions for polypeptide engineering
US64552888 Apr 199324 Sep 2002Dade Behring Marburg GmbhHomogeneous immunoassays using mutant glucose-6-phosphate dehydrogenases
US645855719 Nov 19981 Oct 2002Genencor International, Inc.Culturing microorganism in presence of formate where cell is transformed with polynucleotide sequence which encodes a formate transporter associated protein; production of proteins in culture
US647578914 Aug 19975 Nov 2002University Technology CorporationHuman telomerase catalytic subunit: diagnostic and therapeutic methods
US647926311 Apr 199712 Nov 2002Baylor College Of MedicineMethod for detection of micrometastatic prostate cancer
US648930918 May 19993 Dec 2002Dade Behring Marburg GmbhPolysaccharide conjugates of biomolecules
US650657914 Jul 199814 Jan 2003Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms using SecG
US652142115 Jul 199818 Feb 2003Genencor International, Inc.Expression vectors encoding Bacillus subtilis disulfide bond isomerase and methods of secreting proteins in gram-positive microorganisms using the same
US65214408 Sep 199818 Feb 2003Genencor International, Inc.Proteases from gram-positive organisms
US653113028 Jun 200011 Mar 2003The Board Of Trustees Of The Leland Stanford UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US653781513 Dec 200025 Mar 2003University Of North Texas, Health Science Center At Fort WorthMethod of altering the expression of csrB to modify the properties of a cell
US654479214 Jun 20008 Apr 2003Genencor International, Inc.Deactivation; Bacillus culture product
US657967820 Oct 200017 Jun 2003Maxygen, Inc.Identifying evolved polynucleotides using recursive sequence recombination; recombining overlapping nucleotide sequences; screening for desired property; use in correlating different combinations of mutations with a desired result
US659973117 Dec 199829 Jul 2003Genencor International, Inc.Proteases from gram positive organisms
US660250213 May 19915 Aug 2003Meir StrahilevitzImproved immunoassays of psychotomimetic drugs, narcotic drugs, tetrahydrocannabinols; use of the haptenic properties of psychoactive material; blood test N,N-Dimethyltryptamine and 5-Methoxy-N,N- Dimethyltryptamine
US66108391 Oct 199726 Aug 2003Geron CorporationPromoter for telomerase reverse transcriptase
US661351427 Apr 20002 Sep 2003Maxygen, Inc.Evolving preferential protein; digest nuclelotide sequences substrate, join terminals, screen for preferential proteins, recover nucleotide sequences
US661711022 Nov 20009 Sep 2003Geron CorporationCells immortalized with telomerase reverse transcriptase for use in drug screening
US66303285 Jul 20017 Oct 2003Genencor International, Inc.Increasing production of proteins in gram-positive microorganisms
US664202714 Nov 20014 Nov 2003Genecor International, Inc.Production of secreted polypeptides
US665307224 Jun 199925 Nov 2003Maxygen, Inc.Improving expression of a protein encoded by DNA substrate by assembling oligonucleotides into recombinant nucleic acids and using it to transform cells; recursive sequence recombination
US666437015 Jul 199916 Dec 2003University Of WashingtonImmune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated
US667019613 May 199830 Dec 2003Biosite, Inc.Without measuring the absolute concentrations of the biological molecules by using a binding molecule, preferably an antibody, that recognizes each of the biological molecules but binds only one at a time
US667362312 Sep 20006 Jan 2004Novocure, Inc.Human extra-cellular matrix protein 1 (ecm-1), human glia-derived nexin i alpha protein (np-i), human tissue inhibitor of metalloproteinase-2 (timp-2) and human histone h2a (h2a) are used to control lipogenesis t
US667391421 Jan 19996 Jan 2004John Wayne Cancer InstituteHuman tumor-associated gene
US669996928 Nov 20002 Mar 2004The Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US672355014 Jul 199820 Apr 2004Genencor International, Inc.Proteases from gram-positive organisms
US67592436 Dec 20006 Jul 2004Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US67941792 Jul 200221 Sep 2004Genencor International, Inc.Proteases from gram positive organisms
US680888019 Jan 200126 Oct 2004Geron CorporationMethod for detecting polynucleotides encoding telomerase
US683326126 Mar 200321 Dec 2004Genencor International, Inc.Such as serine proteases from Bacillus for use in cleaning compositions
US683326517 Aug 200121 Dec 2004Genencor International, Inc.Proteases from gram-positive organisms
US68334411 Aug 200121 Dec 2004Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
US68444332 Jun 200318 Jan 2005Affymetrix, Inc.Nucleic acid labeling compounds
US684944026 Mar 20031 Feb 2005Genencor International, Inc.Proteases from gram-positive organisms
US685269521 Mar 20028 Feb 2005Theracos, Inc.For therapy of hyperglycemic disorders
US685871113 Jun 200122 Feb 2005Affymetrix, Inc.Labeling reagents
US68640595 Dec 20028 Mar 2005Affymetrix, Inc.Coupling a nucleic acid labeling compound (a biotin compound attached to a nucleic acid base derivative containing triphosphate) with a nucleic acid
US687253713 Apr 199929 Mar 2005Regents Of The University Of CaliforniaAssays for the detection of microtubule depolymerization inhibitors
US687280712 Jun 200329 Mar 2005Genencor International, Inc.Proteases from gram positive organisms
US688156226 Mar 200319 Apr 2005Genencor International, Inc.Proteases from gram-positive organisms
US68876694 Apr 20003 May 2005Dade Behring Marburg GmbhReagents for assays for ligands
US690586823 Dec 200214 Jun 2005Genencor International, Inc.Cleaning compounds; animal feeds
US691133326 Mar 200328 Jun 2005Genencor International, Inc.Gene has a mutation or deletion of part of the genes, encoding a serine protease cleaning composition; biosynthesis
US692166418 Jan 200226 Jul 2005Regents Of The University Of ColoradoTelomerase
US692409428 Nov 20002 Aug 2005Affymetrix, Inc.Chip-based species identification and phenotypic characterization of microorganisms
US692728512 Nov 19999 Aug 2005Geron CorporationGenes for human telomerase reverse transcriptase and telomerase variants
US694629612 Sep 200120 Sep 2005Maxygen, Inc.Methods and compositions for polypeptide engineering
US69495242 Jul 200227 Sep 2005Dade Behring Marburg GmbhMedicine and clinical chemistry
US69535736 Oct 199811 Oct 2005University Of WashingtonCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US695821412 Apr 200125 Oct 2005Sequenom, Inc.Polymorphic kinase anchor proteins and nucleic acids encoding the same
US696502011 Sep 200115 Nov 2005Affymetrix, Inc.Nucleic acid labeling compounds
US700526218 Jan 200228 Feb 2006Geron CorporationMethods for detecting nucleic acids encoding human telomerase reverse transcriptase
US70259613 Mar 200011 Apr 2006The United States Of America As Represented By The Department Of Health And Human ServicesAnti-plasmodium composition and methods of use
US703022815 Nov 200018 Apr 2006Miltenyi Biotec GmbhMonoclonal antibody for binding antigen, specific for an epitope of antigen; conjugated with radioactive isotops, fluorescents; immunotherapy for treating inflammation, autoimmune diseases
US703381721 Jun 200225 Apr 2006Genencor International, Inc.Proteases from gram positive organisms
US70377149 Jan 20032 May 2006Genencor International, Inc.Chaperone proteins; disulfide bond isomerases; catalyst for folding proteins
US704559614 May 200216 May 2006Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US704560420 Nov 200216 May 2006Tanox, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US705318824 Feb 200330 May 2006Purdue Research FoundationDiagnosis of cancer tissue; monoclonal antibodies
US70532102 Jul 200330 May 2006Health Research, Inc.Efficient synthesis of pyropheophorbide a and its derivatives
US705326815 Jun 200030 May 2006Danisco A/SPromoter
US705651326 Apr 20016 Jun 2006Geron CorporationTelomerase
US707078020 May 20024 Jul 2006Board Of Trustees Of The Leland Stanford Junior UniversityTreatment of demyelinating autoimmune disease with ordered peptides
US707081924 Aug 20044 Jul 2006Genencor International, Inc.metalloprotease having a specific amino acid sequence and further comprising an animal feed enzyme premix, a bacteriolytic enzyme, a xylanase, a subtilisin protease, a cellulase and a beta-glucanase
US707098624 Aug 20044 Jul 2006Genencor International, Inc.Proteases from gram positive organisms
US707099024 Aug 20044 Jul 2006Genencor International, Inc.Mutant nucleic acid; applying to textiles; animal feeds; genetic engineering
US707821631 Oct 200218 Jul 2006Genencor International, Inc.Nucleic acid and amino acid sequences of metalloproteases identified in Bacillus; genetic engineering; for use in cleaning compositions, animal feeds, and textiles
US707837224 Aug 200418 Jul 2006Genencor International, Inc.Proteases from gram positive organisms
US70784953 Aug 199918 Jul 2006Dade Behring Inc.minimal cross reactivity with tacolimus metaolites; antibody is conjugated with a detectable label; sample reacted with an enzyme labelled tacrolimus analogue, total signal present is measured; test kits
US708739516 Jan 20018 Aug 2006Quest Diagnostics Investments IncorporatedDetermination concentration of vitamin d; releasing using aqueous base; solvent-free; coupling to antibody; detection signal
US709802116 Dec 200429 Aug 2006Genencor International, Inc.isolated grampositive microorganism having a mutation or deletion of part or all of the nucleic acid encoding a metalloprotease, said mutation or deletion resulting in the inactivation of the metalloprotease proteolytic activity
US71089682 Apr 199919 Sep 2006Affymetrix, Inc.Mycobacterial rpoB sequences
US711572222 May 19973 Oct 2006Viventia Biotech, Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
US716620817 Feb 200523 Jan 2007Stephen Eliot ZweigCombining dry reagent electrochemical enzyme based biosensors with apoenzyme reactivation technology to produce a novel combination dry reagent test platform technology capable of detecting a wide range of different analytes, for detecting an antigen in a liquid sample
US716628629 Aug 200323 Jan 2007Viventia Biotech Inc.Antigen binding fragments that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for prophylaxis and detection of cancers
US71759832 Nov 200113 Feb 2007Abmaxis, Inc.Adapter-directed display systems
US71799052 Jun 200320 Feb 2007Affymetrix, Inc.Nucleic acid labeling compounds
US718955525 Aug 200413 Mar 2007Genecor International, Inc.Proteases from gram-positive organisms
US719255511 Oct 200120 Mar 2007Orasure Technologies, Inc.Device for collection and assay of oral fluids
US719591111 Jan 200227 Mar 2007Geron CorporationMammalian cells that have increased proliferative capacity
US719923420 Dec 20023 Apr 2007Geron CorporationNucleotide sequences coding telomerase reverse transcriptase (TRT) for diagnosing and treating cancers; antiproliferative agents
US720204229 Oct 200310 Apr 2007Biosite IncorporatedRapid evaluation of the ratio of biological molecules
US722071625 Aug 200422 May 2007Genencor International, Inc.Bacillus; for use in the generation of heterologous protein for use in treatment of textiles, cleaning compositions and animal feeds
US724157525 Aug 200410 Jul 2007Genecor International, Inc.Proteases from gram-positive organisms
US724770321 Aug 200324 Jul 2007University Of WashingtonAnticancer agents; protein complex
US72529484 Feb 20057 Aug 2007Affymetrix, Inc.Using oligonucleotide sequences based on the Mycobacterium tubercluosis rpoB gene by comparing hybridization patterns of target nucleic organism to hybridization patterns in a database; diagnosis of drug resistance in HIV patients
US72529503 Sep 19987 Aug 2007The Regents Of The University Of CaliforniaAssays for detecting modulators of cytoskeletal function
US726228822 Nov 200028 Aug 2007Geron CorporationNucleic acids encoding human telomerase reverse transcriptase and related homologs
US7267957 *26 Apr 200211 Sep 2007Kent State UniversityIncorporation of highly specific receptors into an amplification mechanism, including antibody-embedded liquid crystalline materials, for the rapid and automatic detection of ligands, particularly pathogens and/or their toxins; can be used for early diagnoses
US728232715 Aug 200316 Oct 2007Affymetrix, Inc.Pyrimidine base containing compound suitable for enzymatic attachment to a nucleic acid, to provide a mechanism of nucleic acid detection
US728563918 Jan 200223 Oct 2007Geron CorporationAntibody to telomerase reverse transcriptase
US729146323 Dec 20036 Nov 2007Affymetrix, Inc.Incubating/condensating pseudoisocytidine molecule with (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride to provide a pseudouridine molecule; oncology diagnosis
US730375129 Jul 20034 Dec 2007The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesP. falciparum erythrocyte binding protein-2 (EBP2) Region II (RII), used to induce an immune response to Plasmodium falciparum merozoites to treat diseases such as malaria
US731692016 Dec 20048 Jan 2008Genencor International, Inc.Serine proteases from gram-positive microorganisms
US731692417 Sep 20018 Jan 2008Genencor International, Inc.Chimeric polypeptides for use as gene expression tool in genetic engineering
US73207867 Dec 200522 Jan 2008Light Sciences Oncology, Inc.Administering lyposomes of photosensitive receptors or ligands targeted to specific tissues, exposure to light causing destruction of bound tissues; treatment of eye neovascular disease due to macular degeneration, diabetes
US73265318 Dec 20045 Feb 2008Genencor International, Inc.Proteases from gram-positive organisms
US732952516 Dec 200412 Feb 2008Genencor International, Inc.Bacillus serine proteases for use as active agent in cleaning compounds and detergents
US732952616 Dec 200412 Feb 2008Genencor International, Inc.Serine proteases from-gram-positive microorganisms
US732952716 Dec 200412 Feb 2008Genencor International, Inc.Expression vector comprising nucleotide sequences coding serine protease for use as proteolytic agent in cleaning products
US73550795 Apr 20058 Apr 2008The Regents Of The University Of CaliforniaThyronamine derivatives and analogs and methods of use thereof
US737824425 Apr 200627 May 2008Geron Corporationcombining a polynucleotide containing a promoter sequence which promotes transcription of the genetic element in cells expressing TERT, such as cancer cells and stem cells that can undergo extensive replication, with a protein that binds to promoter and modulates telomerase expression
US73904898 Oct 200424 Jun 2008Komed Co., Ltd.Monoclonal antibody selectively recognizing listeria monocytogenes, hybridoma producing the antibody, test kit comprising the antibody and detection method of listeria monocytogenes using the antibody
US739369624 Sep 20021 Jul 2008Aspenbio Pharma, Inc.Bovine pregnancy test
US74077916 Aug 20035 Aug 2008Genencor International, Inc.cell comprising a peptide transport operon mutated such that said cell has increased polypeptide secretion
US741386424 Jun 200419 Aug 2008Geron CorporationA nucleic acid expression vector encodes the catalytic subunit of human telomerase reverse transcriptase (hTRT); immunostimulants; anticarcinogenic agents; gene therapy
US742314310 May 20059 Sep 2008Affymetrix. Inc.Coupling via incubating with transferase; solid phase synthesis
US74296523 Aug 200430 Sep 2008Abmaxis, Inc.Expression vector comprising nucleotide sequences coding non-single-chain antigen-binding units for use in generating immunoglobulins for diagnosing and treating human disease
US74323421 May 20037 Oct 2008Sequenom, Inc.Kinase anchor protein muteins, peptides thereof and related documents
US744277823 Sep 200528 Oct 2008Amgen Inc.Modified Fc molecules
US746554411 Jan 200616 Dec 2008Wisconsin Alumni Research FoundationSAM analogs that are ligated to a methylation site by the methyltransferase
US746570510 Feb 200516 Dec 2008Yale UniversityImmunogenic Nogo receptor-1 polypeptides, Nogo receptor-1 antibodies; diabetic neuropathy; brain injury, spinal cord injury
US746824312 Mar 200223 Dec 2008Affymetrix, Inc.2-aminopyrimidin-4-one nucleic acid labeling compounds
US749181818 Jan 200517 Feb 2009Affymetrix, Inc.Oncology diagnosis; gene overexpression/underexpression; tumor suppressor genes
US749508925 Mar 200524 Feb 2009The Children's Medical Center CorporationInhibit endothelial cell proliferation, angiogenesis and cause tumor regression; antiproliferative, anticarcinogenic and antitumor agents
US750150914 Jun 200610 Mar 2009Health Research, Inc.A tetrapyrollic photosensitizer compound having at least one pendant CH2CH2CON(CH2CON(CH2COOH)2)2 or N(CH2COOH)2 group, being a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide
US751797122 Nov 200014 Apr 2009Geron Corporationrecombinant polynucleotide encoding activity-modified polypeptides, useful for medical diagnosis and prognosis, changing the proliferative capacity of cells and organisms, drug screening and treatment of diseases such as cancers
US754119417 Jan 20072 Jun 2009Orasure Technologies, Inc.Device for collection and assay of oral fluids
US75602394 Jun 200214 Jul 2009Lin-Zhi International Inc.Homogeneous enzyme immunoassay for simultaneous detection of multiple analytes
US756043711 Jan 200214 Jul 2009Geron CorporationTherapeutic agent for use in the diagnosis and treatment of cancer and cell proliferative disorders
US756935720 Feb 20044 Aug 2009Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
US757618714 Jul 200618 Aug 2009Genentech, Inc.Family of genes encoding apoptosis-related peptides, peptides encoded thereby and methods of use thereof
US75856222 Nov 19998 Sep 2009Geron CorporationIncreasing the proliferative capacity of cells using telomerase reverse transcriptase
US76016973 May 200513 Oct 2009University Of WashingtonPolypeptides; nucleic acid molecules and viral vectors which direct gene expression of such polypeptides; vaccines; genetic engineering; transfecting cells of animal ex vivo with nucleic acid molecule and delivering transfected cells animal
US760839515 Sep 200527 Oct 2009Baylor Research InstitutePredicts the likelihood of renal involvement, diagnose SLE, distinguish SLE gene expression profiles from profiles of patients infected with influenza, and to monitor disease progression and treatment
US760841529 Jun 200527 Oct 2009Discoverx CorporationEmploying a genetically modified cell expressing one or more proteins of interest fused to a fragment that is a member of an enzyme fragment complementation ("EFC") pair; Western blotting; high sensitivity and the ability to observe modifications of the target protein
US76187893 Apr 200217 Nov 2009The United States Of America As Represented By The Secretary Of Department Of Health And Human ServicesUse of semenogelin in the diagnosis, prognosis and treatment of cancer
US762254924 Jun 200424 Nov 2009Geron CorporationHuman telomerase reverse transcriptase polypeptides
US764190415 Feb 20085 Jan 2010Konkuk University Industrial Cooperation Corp.IL-32 monoclonal antibodies and uses thereof
US764233820 Jun 20065 Jan 2010Siemens Healthcare Diagnostics Inc.Determining a concentration of tacrolimus or derivative thereof in a sample; using a non-specific protein capable of forming a water soluble complex with the tacrolimus
US76458611 Aug 200812 Jan 2010Amgen Inc.Modified Fc molecules
US765523921 Jun 20072 Feb 2010University Of WashingtonPeptides for use in diagnosis, prevention and treatment of cell proliferative disorders
US76557641 Aug 20082 Feb 2010Amgen Inc.immunoglobulin domain peptides having myostatin, erythropoietin or thrombopoietin peptides as an internal sequence, preferably in a loop region of the domain; antibodies
US76557651 Aug 20082 Feb 2010Amgen Inc.Modified Fc molecules
US76629311 Aug 200816 Feb 2010Amgen Inc.immunoglobulin domain peptides having myostatin, erythropoietin or thrombopoietin peptides as an internal sequence, preferably in a loop region of the domain; antibodies
US766865815 Oct 200223 Feb 2010Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US768728113 Mar 200730 Mar 2010Aspenbio Pharma, Inc.On-site immunoassaying of ruminants and ungulate animals by testing for the presence, absence, or particular level of selected Antigens A and/or B and C in a sample from a female animal; resynchronizing breeding with breeding cycle times of one estrus cycle or shorter; animal husbandry; efficiency
US77089844 Jun 20074 May 2010Incyte CorporationUsing immunoglobulin specific to adenoid expressed chemokine (ADEC) for prevention and treatment of cell proliferative, glandular and viral infection
US770927212 Aug 20034 May 2010N-Dia, Inc.Devices and methods for detecting amniotic fluid in vaginal secretions
US77321533 May 20078 Jun 2010Beckman Coulter, Inc.use of an immobilized chemiluminescent compound and an activator compound conjugated to a specific binding partner for inducing a chemiluminescent reaction; does not require removal or separation of excess detection label prior to the detection step
US773221910 Sep 20078 Jun 2010Kent State UniversityDetection and amplification of ligands
US775012117 Aug 20056 Jul 2010Geron CorporationA recombinant human telomerase reverse transcriptase (hTRT) protein; drug screening for antiproliferative agents that inhibit hTRT activity; cancer diagnosis and prognosis; anticarcinogenic agents
US77501271 Aug 20086 Jul 2010Amgen Inc.Modified Fc molecules
US77501281 Aug 20086 Jul 2010Amgen Inc.Modified Fc molecules
US777196015 Oct 200810 Aug 2010Idexx Laboratories, Inc.determining the presence or amount of feline pancreatic lipase in a biological sample; generation of monoclonal antibodies that specifically binds to the feline pancreatic lipase polypeptides, and cell lines secreting the monoclonal antibodies
US777687717 Jun 200817 Aug 2010Chemocentryx, Inc.N-(4-Chloro-2-[1,2,3]triazolo[4,5-b]pyridin-1-yl-phenyl)-4-(1-hydroxy-1-methyl-ethyl)-benzene-sulfonamide sodium salt, used as chemokine receptors antagonists, useful for treating inflammation
US778589830 May 200331 Aug 2010Genetic Technologies Limitedobtaining a sample of maternal blood that contains fetal cells, detecting and distinguishing a maternal antibody from the mother bound to a paternally inherited fetal antigen on the fetal cell which formed a fetal cell-maternal antibody complex, to thereby identify the fetal cell
US77995348 May 200721 Sep 2010Beckman Coulter, Inc.Nonseparation assay methods
US782014319 Feb 200926 Oct 2010Health Research, Inc.Water soluble tetrapyrollic photosensitizers for photodynamic therapy
US782931324 May 20069 Nov 2010Eppendorf Array TechnologiesIdentification and quantification of a plurality of biological (micro)organisms or their components
US78425132 May 200330 Nov 2010Aspenbio Pharma, Inc.Preparing immunoglobulin for use as tool in immunoassay for determining pregnancy in ruminants; animal husbandry; in vito fertilization; veterinary medicine
US784666720 Aug 20097 Dec 2010Genzyme CorporationUsing myeloblastosis oncogene expression profile as tool in detection of cell proliferative disorders associated with respiratory system
US786797515 Dec 200811 Jan 2011The Children's Medical Center Corporationadministering a nucleic acid comprising a coding region encoding endostatin; inhibiting angiogenesis in an angiogenesis-dependent site associated with macular degeneration; antiproliferative, anticarcinogenic and antitumor agents
US787544217 May 200625 Jan 2011Eppendorf Array TechnologiesUsing primer amplification to identify and quantify presence of preferential amplicons in solution
US78757135 Sep 200425 Jan 2011Technion Research & Development Foundation Ltd.Synthetic binding pairs comprising cucurbituril derivatives and polyammonium compounds and uses thereof
US787960926 Mar 20071 Feb 2011Geron CorporationRegulatory segments of the human gene for telomerase reverse transcriptase
US788387620 Nov 20078 Feb 2011Stephens David SNeisseria meningitidis serogroup A capsular polysaccharide acetyltransferase, methods and compositions
US788411011 Jul 20088 Feb 2011Chemocentryx, Inc.4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidine-4-carbonyl)-pyridin-3-yl]-3-trifluoromethyl-benzenesulfonamide sodium salt; for chemokine-mediated conditions or diseases including certain inflammatory and immunoregulatory disorders; restenosis, multiple sclerosis, arthritis
US78841911 Jun 20078 Feb 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US78841921 Jun 20078 Feb 2011Danisco Us Inc.Twin-arginine translocation in Bacillus
US789714030 Jun 20061 Mar 2011Health Research, Inc.Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US78977421 Jun 20071 Mar 2011Danisco Us Inc.Nucleotide sequences coding phospholipase; screening and identifying grampositive mocroorganisms
US791035019 Dec 200522 Mar 2011Abmaxis, Inc.Adaptor-directed helper systems
US792782721 May 200719 Apr 2011Kent State UniversityDetection and amplification of ligands
US79558137 Jul 20067 Jun 2011Danisco, A/SMethod of using lipid acyltransferase
US79558146 Feb 20077 Jun 2011Danisco A/SMethod
US796015020 Jul 200914 Jun 2011Danisco A/SProduction of a lipid acyltransferase from transformed Bacillus licheniformis cells
US797263814 Oct 20085 Jul 2011Danisco A/SFoodstuff
US79855427 Sep 200626 Jul 2011Institut PasteurUsing microarrays comprising immobilized probes as tools in detection of preferential macromolecules
US799383012 Feb 20079 Aug 2011Laboratory Corporation Of America HoldingsProstate-specific gene for diagnosis, prognosis and management of prostate cancer
US80030957 Jul 200623 Aug 2011Danisco A/SMethod of using lipid acyltransferase
US800800818 Oct 200730 Aug 2011Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
US800802724 Mar 201030 Aug 2011Incyte CorporationMethods of screening for compounds that modulate the activity of ADEC, a chemokine expressed in inflamed adenoid
US800845310 Aug 200630 Aug 2011Amgen Inc.immunoglobulin domain peptides having myostatin, erythropoietin or thrombopoietin peptides as an internal sequence, preferably in a loop region of the domain; antibodies
US80127322 Sep 20096 Sep 2011Danisco A/SFungal lypolytic and amylase enzyme composition and methods using the same
US802605727 Jun 200827 Sep 2011Affymetrix, Inc.Nucleic acid labeling compounds
US803004429 Feb 20084 Oct 2011Danisco A/SLipid acyltransferases
US803045615 Dec 20084 Oct 2011Yale UniversityNogo receptor antagonists
US803045826 Sep 20084 Oct 2011Siemens Healthcare Diagnostics Inc.Monoclonal antibodies to tacrolimus and immunoassays methods for tacrolimus
US803455324 Jun 200411 Oct 2011Kimberly-Clark Worldwide, Inc.Biomarkers for wound healing
US803457618 Dec 200911 Oct 2011Naturon, Inc.Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US805051613 Sep 20071 Nov 2011Fluidigm CorporationMethods and systems for determining a baseline during image processing
US805322118 Apr 20078 Nov 2011Danisco A/SEnzymes
US805503413 Sep 20078 Nov 2011Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US80629088 Jan 200922 Nov 2011Orasure Technologies, Inc.Device for collection and assay of oral fluids
US806716412 Aug 200829 Nov 2011Integrated Dna Technologies, Inc.Microarray system with improved sequence specificity
US806724022 Nov 201029 Nov 2011Esoterix Genetic Laboratories, LlcMethods for the diagnosis and treatment of lung cancer
US80713236 Apr 20076 Dec 2011The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesHuman monoclonal antibodies that bind human insulin like growth factors and their use
US807607228 Sep 201013 Dec 2011Affymetrix, Inc.Nucleic acid labeling compounds
US81015638 Dec 200424 Jan 2012Danisco Us Inc.Proteases from gram-positive organisms
US811461011 Mar 201014 Feb 2012N-Dia, Inc.Devices and methods for detecting amniotic fluid in vaginal secretions
US811461919 Sep 200714 Feb 2012The Johns Hopkins UniversityMethods for diagnosis and optimizing treatment of multiple sclerosis
US811899122 Jan 200721 Feb 2012Stephen Eliot ZweigApoenzyme reactivation electrochemical detection method and assay
US813831610 Jun 201020 Mar 2012Idexx Laboratories, Inc.Feline pancreatic lipase
US81430453 Apr 200727 Mar 2012Danisco A/SMutant Citrobacter freundii phytase polypeptide
US81430466 Feb 200827 Mar 2012Danisco Us Inc., Genencor DivisionVariant Buttiauxella sp. phytases having altered properties
US815359418 Nov 200910 Apr 2012Siemens Healthcare Diagnostics Inc.Tacrolimus standard and methods of using same
US816331513 Apr 201124 Apr 2012Danisco A/SFoodstuff
US817338217 Aug 20108 May 2012Abbott LaboratoriesAssay for cardiac troponin autoantibodies
US81830023 Dec 200922 May 2012Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US818303929 Mar 200622 May 2012Miltenyi Biotec GmbhMethod for isolating BDCA-4+ dendritic cells
US819278216 Jan 20075 Jun 2012Danisco A/SEnzymatic oil-degumming method
US81983098 Jul 201012 Jun 2012Chemocentryx, Inc.N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl)hetaryl arylsulfonamides
US822239220 Aug 200717 Jul 2012Geron CorporationKit for detection of telomerase reverse transcriptase nucleic acids
US822967721 Dec 200924 Jul 2012Sequenom, Inc.Methods for generating databases and databases for identifying polymorphic genetic markers
US82364937 Aug 20087 Aug 2012Affymetrix, Inc.Methods of enzymatic discrimination enhancement and surface-bound double-stranded DNA
US823677421 Aug 20097 Aug 2012Geron CorporationHuman telomerase catalytic subunit
US82780629 Mar 20092 Oct 2012Dupont Nutrition Biosciences ApsMethod of using lipid acyltransferase
US827809828 Jan 20112 Oct 2012Vegenics Pty LimitedMaterials and methods involving hybrid vascular endothelial growth factor DNAs and proteins
US828812818 Nov 200416 Oct 2012Eppendorf Array Technologies S.A.Real-time quantification of multiple targets on a micro-array
US829368429 Nov 200723 Oct 2012ExiqonLocked nucleic acid reagents for labelling nucleic acids
US830420119 Apr 20126 Nov 2012Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US831889822 Dec 200627 Nov 2012Universite De LausanneSynthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of cellular relaxation
US835749524 Apr 200922 Jan 2013Abbott LaboratoriesImmunoassay of analytes in samples containing endogenous anti-analyte antibodies
US836173410 Oct 201129 Jan 2013Naturon, Inc.Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
US83776479 Dec 201119 Feb 2013Beckman Coulter, Inc.Nonseparation assay methods
US83945825 Mar 200412 Mar 2013Genetic Technologies, IncIdentification of fetal DNA and fetal cell markers in maternal plasma or serum
US844043525 Jun 200914 May 2013Dupont Nutrition Biosciences ApsMethod for reducing 1,2-diglyceride content of an edible oil
US844522211 Jul 200721 May 2013Musc Foundation For Research DevelopmentPredicting heart failure following myocardial infarction by protease and protease inhibitor profiling
US84456377 Dec 200921 May 2013Abraxis Bioscience, LlcSPARC binding peptides and uses thereof
US847321630 Nov 200725 Jun 2013Fluidigm CorporationMethod and program for performing baseline correction of amplification curves in a PCR experiment
US848133331 May 20129 Jul 2013Idexx Laboratories, Inc.Detection of degradation products of feline NT-proBNP
US848169819 Mar 20099 Jul 2013The President And Fellows Of Harvard CollegeParallel proximity ligation event analysis
US84970641 Nov 201130 Jul 2013Affymetrix, Inc.Nucleic acid labelling compounds
US849734922 Apr 200730 Jul 2013Centre National De La Recherche Scientifique (Cnrs)Use of multivalent synthetic ligands of surface nucleolin for treating cancer or inflammation
US85064994 Jan 200813 Aug 2013Musc Foundation For Research DevelopmentPredicting atrial fibrillation recurrence by protease and protease inhibitor profiling
US85244914 Sep 20093 Sep 2013University Of Washington Through Its Center For CommercializationCompounds for eliciting or enhancing immune reactivity to HER-2/neu protein for prevention or treatment of malignancies in which the HER-2/neu oncogene is associated
US85359001 Feb 201017 Sep 2013Dupont Nutrition Biosciences ApsLipolytic enzyme uses thereof in the food industry
US854640822 Dec 20101 Oct 2013Chemocentryx, Inc.Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation
US85748287 Sep 20105 Nov 2013Accumetrics, Inc.Controlled platelet activation to monitor therapy of ADP antagonists
US85748323 Feb 20105 Nov 2013Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
US85748582 Oct 20125 Nov 2013Abbott LaboratoriesAutoantibody enhanced immunoassays and kits
US85867235 Sep 200719 Nov 2013Institut PasteurGenomic morse code
US859215111 Nov 201026 Nov 2013Musc Foundation For Research DevelopmentAssessing left ventricular remodeling via temporal detection and measurement of microRNA in body fluids
US86001685 Oct 20113 Dec 2013Fluidigm CorporationMethods and systems for image processing of microfluidic devices
US861755110 Aug 201031 Dec 2013Incyte CorporationMethods of diagnosing pancreatic inflammation by using chemokine PANEC-1 antibodies
US864229510 Jan 20084 Feb 2014Erasmus University Medical CenterCircular chromosome conformation capture (4C)
US86423308 Aug 20064 Feb 2014Onconon, LlcAntibody compositions, methods for treating neoplastic disease and methods for regulating fertility
US86527883 Dec 200918 Feb 2014Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
US865280916 Feb 201018 Feb 2014Dupont Nutrition Biosciences ApsMethod for producing ultra-heat treatment milk
US866910129 Dec 201011 Mar 2014Engeneic Molecular Delivery Pty. Ltd.Bacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US866934526 Jan 200711 Mar 2014Biogen Idec Ma Inc.Nogo receptor antagonists
US868540227 Jul 20091 Apr 2014Institute For Research In BiomedicineNeutralizing anti-influenza A virus antibodies and uses thereof
US869196325 Aug 20058 Apr 2014Engeneic Molecular Delivery Pty. Ltd.Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
US870999520 Aug 200729 Apr 2014Geron CorporationMethod for eliciting an immune response to human telomerase reverse transcriptase
US871566511 Apr 20086 May 2014The General Hospital CorporationMethods for treating cancer resistant to ErbB therapeutics
US871596029 Mar 20106 May 2014Mitomics Inc.Aberrant mitochondrial DNA, associated fusion transcripts and translation products and hybridization probes therefor
US872286618 Jan 200713 May 2014The United States Of America, As Represented By The Department Of Veterans AffairsIsoform-selective inhibitors and activators of PDE3 cyclic nucleotide phosphodiesterases
US873556621 Mar 200827 May 2014Engeneic Molecular Delivery Pty LtdBacterially derived intact minicells that encompass plasmid free functional nucleic acid for in vivo delivery to mammalian cells
US87786994 Aug 201115 Jul 2014Idexx Laboratories, Inc.Detection of degradation products of canine NT-proBNP
USRE32696 *22 Dec 197814 Jun 1988Akzona IncorporatedEnzymatic immunological method for determination of antigens and antibodies
USRE4313520 Sep 200724 Jan 2012Danisco A/SMethod of improving dough and bread quality
USRE4327423 Jan 200927 Mar 2012Health Research, Inc.Fluorinated photosensitizers related to chlorins and bacteriochlorins for photodynamic therapy
DE2521523A1 *14 May 197515 Jan 1976Syva CoLactamverbindungen und konjugate
DE2618511A1 *27 Apr 19764 Nov 1976Miles LabVerfahren zur bestimmung eines liganden in einem fluessigen medium und mittel zu dessen durchfuehrung
DE2660911C2 *10 Feb 197628 May 1986Syva Co., Palo Alto, Calif., UsTitle not available
DE2805961A1 *13 Feb 197819 Oct 1978Syva CoTheophyllin-antigene und -antikoerper und ihre verwendung zur bestimmung von theophyllin
DE2830862A1 *13 Jul 19781 Feb 1979Syva CoHomogener, kompetitiver antienzym- bindungstest und reagenz zur durchfuehrung des verfahrens
DE2913550A1 *4 Apr 197918 Oct 1979Syva CoAnalytisches verfahren und reagens zu dessen durchfuehrung
DE3049711C2 *23 Apr 19805 May 1994Syva CoLadungseffekte bei Immunassays
DE3227474A1 *22 Jul 198210 Feb 1983Fuji Photo Film Co LtdAnalysenfilm und analysenverfahren unter verwendung desselben
DE102006009516A1 *28 Feb 200630 Aug 2007Analyticon Biotechnologies AgTest device for detecting an analyte in a liquid sample comprises a dry porous support with a reaction zone containing an analyte-selective binder, a biomarker/reporter enzyme complex and a reporter substrate
DE102006009516B4 *28 Feb 20066 Dec 2007Analyticon Biotechnologies AgTestvorrichtung, Herstellungsverfahren dafür und Testverfahren
DE212006000071U114 Nov 200624 Jul 2008Board of Regents, The University of Texas System, AustinQuantifizierung von Fusionsproteinen und ihrer Aktivität in Folge chromosomaler Translokation
EP0043285A1 *30 Jun 19816 Jan 1982Dainippon Pharmaceutical Co., Ltd.Method for determination of valproic acid and reagents therein
EP0047455A2 *28 Aug 198117 Mar 1982Syva CompanySingle test compositions for immunoassays and method for their preparation
EP0057731A1 *11 Jul 198018 Aug 1982Syva CompanyValproate derivatives and their conjugates to antigenic materials, antibodies thereto and method for the determination of valproate in physiological fluids
EP0061762A229 Mar 19826 Oct 1982Baker Instruments CorporationNucleotide-based substrates
EP0110640A2 *18 Nov 198313 Jun 1984Minnesota Mining And Manufacturing CompanyReceptor-based histamine assay
EP0117693A2 *17 Feb 19845 Sep 1984The Upjohn CompanyEnzyme-linked immunoassay, assay kits and pair-binding compounds
EP0126631A1 *17 May 198428 Nov 1984Syntex (U.S.A.) Inc.Chloramphenicol derivatives, intermediates and processes therefor
EP0137678A1 *23 Aug 198417 Apr 1985Syntex (U.S.A.) Inc.Ultrasonic enhanced immuno-reactions
EP0185432A2 *18 Dec 198525 Jun 1986SCLAVO S.p.A.Immunoenzymatic method for the determination of analytes, and composition suitable to the purpose
EP0201716A27 Apr 198620 Nov 1986Bristol-Myers Squibb CompanyExpression of immunologically reactive viral proteins
EP0204523A2 *30 May 198610 Dec 1986Syntex (U.S.A.) Inc.Glucose-6-phosphate dehydrogenase conjugates, their preparation and use
EP0421589A2 *13 Aug 199010 Apr 1991Microgenics CorporationDrug screening assay
EP0699754A111 Aug 19956 Mar 1996Myriad Genetics, Inc.Method for diagnosing a predisposition for breast and ovarian cancer
EP0705902A111 Aug 199510 Apr 1996Myriad Genetics, Inc.17q-Linked breast and ovarian cancer susceptibility gene
EP0705903A111 Aug 199510 Apr 1996Myriad Genetics, Inc.In vivo mutations and polymorphisms in the 17q-linked breast and ovarian cancer susceptibility gene
EP0785216A117 Dec 199623 Jul 1997Myriad Genetics, Inc.Chomosome 13-linked breast cancer susceptibility gene BRCA2
EP1333094A21 Oct 19976 Aug 2003Geron CorporationHuman telomerase catalytic subunit
EP1655381A12 Nov 200510 May 2006Affymetrix, Inc. (A US Entity)Nucleic acid labeling methods
EP1696236A229 Mar 199930 Aug 2006OraSure Technologies, Inc.Device for assay of antibodies in oral fluids
EP1728875A27 Feb 19976 Dec 2006Affymetrix, Inc.Chip-based speciation and phenotypic characterization of microorganisms
EP1762243A130 Mar 200014 Mar 2007Oxford Biomedica (UK) LtdFactor for regulation of neurite growth
EP1783139A21 Oct 19979 May 2007Geron CorporationHuman telomerase catalytic subunit
EP1798286A231 Jul 199820 Jun 2007Schering CorporationMammalian cell membrane proteins and related reagents
EP1798287A231 Jul 199820 Jun 2007Schering CorporationMammalian cell membrane proteins and related reagents
EP1803816A212 Dec 19974 Jul 2007Schering CorporationMammalian cell surface antigens; related reagents
EP1897949A220 Sep 199912 Mar 2008Schering CorporationHuman interleukin-B50. Therapeutic uses
EP1905832A28 Sep 20002 Apr 2008Schering CorporationMammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
EP1908837A223 May 20019 Apr 2008Schering CorporationHuman receptor proteins, related reagents and methods
EP1918377A110 May 20017 May 2008Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP1942114A29 Mar 20009 Jul 2008Schering CorporationMammalian cytokines; related reagents and methods
EP1947183A114 Aug 199723 Jul 2008Schering CorporationMammalian cell surface antigens; related reagents
EP1950299A130 May 200030 Jul 2008Schering CorporationMammalian receptor proteins; related reagents and methods
EP1964921A221 Jun 20003 Sep 2008Oscient Pharmaceuticals CorporationThe high bone mass gene of 11q13.3
EP1980573A28 Jul 199815 Oct 2008Schering CorporationIsolated dendritic cell membrane protein genes
EP1983001A223 Sep 199922 Oct 2008Schering CorporationAntibodies to mammalian Langerhans cell antigen and their uses
EP1988166A17 May 19985 Nov 2008Schering CorporationHuman Toll-like receptor proteins, related reagents and methods
EP1990057A117 May 200212 Nov 2008Merck & Co., Inc.Beta-secretase substrates and uses thereof
EP1995317A112 Dec 199726 Nov 2008Schering CorporationMammalian cell surface antigens; related reagents
EP1995318A112 Dec 199726 Nov 2008Schering CorporationMammalian cell surface antigens; related reagents
EP2020239A117 Apr 20014 Feb 2009Schering CorporationUse of IL-174 agonists for treating infectious diseases
EP2026070A19 Sep 200318 Feb 2009Arbor Vita CorporationMethods of diagnosing cervical cancer
EP2028187A17 Sep 200125 Feb 2009Board Of Regents, The University Of Texas SystemHuman and mouse targeting peptides identified by phage display
EP2031070A126 Nov 20034 Mar 2009Applera CorporationMultiplex amplification of polynucleotides
EP2042869A26 Dec 20001 Apr 2009Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2050826A213 Oct 200822 Apr 2009Roche Diagnostics GmbHReagents and methods for detecting neisseria gonorrhoeae
EP2070944A111 Oct 200217 Jun 2009Amgen Inc.Specific binding agents of human angiopoietin-2
EP2072059A111 Oct 200224 Jun 2009Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2077277A130 Jan 20038 Jul 2009Schering CorporationUse of mammalian cytokine; related reagents
EP2100959A224 Jul 199816 Sep 2009Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2107125A131 Mar 20087 Oct 2009Eppendorf Array Technologies SA (EAT)Real-time PCR of targets on a micro-array
EP2119771A223 Dec 200418 Nov 2009Danisco A/SProteins
EP2128270A19 Aug 20042 Dec 2009Genenews Inc.Osteoarthritis biomarkers and uses thereof
EP2131198A220 Sep 20029 Dec 2009Board of Regents, The University of Texas SystemMeasuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays
EP2138510A127 Jul 200030 Dec 2009Schering CorporationMethods of generating antibodies against cytokines
EP2149585A14 Nov 20043 Feb 2010Novartis Vaccines and Diagnostics, Inc.Antagonist anti-CD40 monoclonal antibodies and methods for their use
EP2157097A111 Oct 200224 Feb 2010Amgen, Inc.Specific binding agents of human angiopoietin-2
EP2172210A122 Dec 20067 Apr 2010Partnership&Corp. Technology TransferSynthetic peptides for use as inhibitors of neurotransmitter secretion
EP2172478A26 Feb 19987 Apr 2010THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICESActivity-dependent neurotrophic factor III (ADNF III)
EP2177503A121 Feb 200521 Apr 2010UCL Business PLCModulators of cannabinoid receptors
EP2194147A126 Nov 20039 Jun 2010Applied Biosystems, LLCMultiplex amplification of polynucleotides
EP2202240A117 Aug 200130 Jun 2010Sterix LimitedCompound
EP2204654A112 Aug 20037 Jul 2010N-Dia, Inc.Devices and methods for detecting amniotic fluid in vaginal secretions
EP2208797A21 Mar 200521 Jul 2010Applied Biosystems, LLCMethods, compositions and kits for use in polynucleotide amplification
EP2210899A110 Nov 200528 Jul 2010Danisco A/Spntr transcription factor
EP2213740A11 Oct 19974 Aug 2010The Regents of the University of ColoradoHuman telomerase catalytic subunit
EP2230255A115 Oct 200822 Sep 2010IDEXX Laboratories, Inc.Feline pancreatic lipase
EP2233574A124 Jul 199829 Sep 2010Schering CorporationMammalian cytokine: interleukin-B30 and related reagents
EP2236600A117 Oct 20056 Oct 2010Danisco A/SEnzymes
EP2236601A117 Oct 20056 Oct 2010Danisco A/SPhytases
EP2243491A14 Nov 200427 Oct 2010Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
EP2243492A14 Nov 200427 Oct 2010Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2246444A114 Sep 20053 Nov 2010The Regents of the University of Colorado, A Body CorporateMethod for treatment with bucindolol based on genetic targeting
EP2248830A14 Nov 200410 Nov 2010Novartis Vaccines and Diagnostics, Inc.Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
EP2256203A118 Nov 20041 Dec 2010Schering CorporationIL-23 and its receptor; related reagents and methods
EP2258726A113 Jun 19968 Dec 2010The Regents of the University of CaliforniaHigh affinity human antibodies to c-erbB-2
EP2258849A130 May 20008 Dec 2010Schering CorporationMammalian receptor proteins; related reagents and methods
EP2261256A215 Nov 200015 Dec 2010Schering CorporationMethods of inhibiting metastasis
EP2264156A117 Oct 200522 Dec 2010Danisco A/SPhytases
EP2266405A210 Mar 200529 Dec 2010Danisco A/SFungal lipolytic enzymes
EP2267107A218 Jul 200529 Dec 2010Danisco A/SLipolytic Enzyme. Uses Thereof In The Food Industry
EP2267108A118 Jul 200529 Dec 2010Danisco A/SEnzymatic oil-degumming method
EP2272869A211 Oct 200212 Jan 2011Amgen Inc.Angiopoietin-2 specific binding agents
EP2275447A115 Nov 200019 Jan 2011Schering CorporationMethods of inhibiting metastasis
EP2275522A218 Jul 200519 Jan 2011Danisco A/SEnzymatic oil-degumming method
EP2275548A110 May 200119 Jan 2011Schering CorporationMammalian cytokine receptor subunit proteins, related reagents and methods
EP2278015A115 Jan 200426 Jan 2011Danisco A/SMethod of producing a carbohydrate ester
EP2280285A115 Sep 20042 Feb 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
EP2280286A115 Sep 20042 Feb 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2281841A230 Nov 20059 Feb 2011Schering CorporationBiomarkers for pre-selection of patients for anti-IGF1R therapy
EP2283831A230 Nov 200516 Feb 2011Schering CorporationBiomakers for pre-selection of patients for anti-IGF1R therapy
EP2287185A26 Dec 200023 Feb 2011Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2287317A215 Jan 200423 Feb 2011Danisco A/SMethod of producing a protein ester or a protein subunit ester
EP2287616A115 Sep 200423 Feb 2011Oklahoma Medical Research FoundationMethod of using cytokine assays to diagnose, treat, and evaluate systemic lupus erythematosus
EP2290085A215 Jan 20042 Mar 2011Danisco A/SMethod for the in situ production of an emulsifier in a foodstuff
EP2292661A29 Nov 20049 Mar 2011Schering CorporationInterleukin-10 antibodies
EP2292760A29 Nov 20019 Mar 2011Schering CorporationMammalian cytokines, receptors, related reagents and methods
EP2295978A219 Mar 199916 Mar 2011The Curators Of The University Of MissouriEarly pregnancy diagnosis using PAGs(Pregnancy-associated Glycoproteins)
EP2298789A17 Sep 200123 Mar 2011Schering CorporationMammalian genes; related reagents and methods
EP2301575A14 Nov 200430 Mar 2011Novartis Vaccines and Diagnostics, Inc.Methods of therapy for solid tumors expressing the CD40 cell-surface antigen
EP2302072A118 Nov 200530 Mar 2011Eppendorf Array Technologies S.A.Real time-PCR of targets on a micro-array
EP2302079A215 Sep 200630 Mar 2011Baylor Research InstituteSystemic lupus erythematosus diagnostic assay
EP2311869A130 Jan 200320 Apr 2011Schering CorporationUse of mammalian cytokine; related reagents
EP2312315A118 May 200620 Apr 2011Novartis AGMethods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
EP2314696A120 Sep 199927 Apr 2011Schering CorporationTherapeutic uses of human Interleukin-B50 antagonist.
EP2316485A111 Oct 20024 May 2011Schering CorporationUse of bispecific antibodies to regulate immune responses
EP2316845A111 Oct 20024 May 2011Amgen Inc.Specific binding agents of human angiopoietin-2
EP2319941A223 Oct 200611 May 2011GeneNews Inc.Method and apparatus for correlating levels of biomarker products with disease
EP2330132A14 Apr 20048 Jun 2011Yeda Research and Development Co. Ltd.Antibodies and pharmaceutical compositions containing same useful for inhibiting activity of metalloproteins
EP2336321A111 May 200022 Jun 2011Medical Research CouncilOx2 receptor homolog
EP2336775A26 Dec 200022 Jun 2011Board Of Trustees Of The University Of IllinoisHigh affinity TCR proteins and methods
EP2338913A117 Dec 199629 Jun 2011The University of Utah Research FoundationChromosome 13-linked breast cancer susceptibility gene
EP2339032A118 Apr 200629 Jun 2011Mitomics Inc.Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
EP2341143A111 May 20006 Jul 2011Medical Research CouncilOX2 receptor homolog
EP2341144A110 Jan 20006 Jul 2011Schering CorporationInterleukin-17 related mammalian cytokines. Polynucleotides encoding them. Uses
EP2341346A217 Oct 20016 Jul 2011The Regents of the University of CaliforniaMethods of high-throughput screening for internalizing antibodies and metal-chelating liposomes
EP2341349A13 May 20016 Jul 2011Siemens Healthcare Diagnostics Products GmbHMethods for detection of multiple analytes
EP2343311A25 Sep 200513 Jul 2011Licentia OyPeptide inhibitors of HK2 and their use
EP2354160A129 Aug 200610 Aug 2011Schering CorporationEngineered anti-IL-23-antibodies
EP2359832A225 Jul 200524 Aug 2011University of Maryland, BaltimoreTherapeutic agents targeting the NCCA-ATP channel and methods of use thereof
EP2364994A13 Jan 199514 Sep 2011Schering CorporationPurfied primate CTLA-8 antigens and related reagents
EP2382977A116 Sep 20052 Nov 2011University of Maryland, BaltimoreTherapeutic agents targeting the ncca-atp channel and methods of use thereof
EP2385124A212 May 20009 Nov 2011Arbor Vita CorporationPeptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
EP2386640A225 Aug 200516 Nov 2011EnGeneIC Molecular Delivery Pty LtdDelivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells
EP2389943A117 Apr 200130 Nov 2011Schering CorporationUse of IL-174 antagonists for treating Th2-related diseases
EP2395025A126 Feb 200814 Dec 2011Schering CorporationEngineered Anti-IL-23R Antibodies
EP2400030A118 May 200528 Dec 2011The Board Of Trustees Of The University Of the Leland Stanford Junior UniversityDetection of protein translocation by beta-galactosidase reporter fragment complementation
EP2402752A229 Oct 20074 Jan 2012Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2405007A125 Jan 200711 Jan 2012Danisco A/SProduction of a lipid acyltransferase from transformed bacillus cells
EP2407242A113 Jul 201018 Jan 2012Dublin City UniversityDirect clone analysis and selection technology
EP2407783A129 Oct 200718 Jan 2012Janssen Pharmaceutica, N.V.A method for pharmacologically profiling compounds
EP2423332A123 Aug 200729 Feb 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2423333A123 Aug 200729 Feb 2012Oncotherapy Science, Inc.Prognostic markers and therapeutic targets for lung cancer
EP2425850A214 Jun 20067 Mar 2012The Regents of The University of CaliforniaBispecific single chain FV antibody molecules and methods of use thereof
EP2425860A111 Aug 20067 Mar 2012Amgen Inc.Modified Fc molecules
EP2426144A121 Feb 20087 Mar 2012Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426145A121 Feb 20087 Mar 2012Schering CorporationEngineered anti-IL-23p19 antibodies
EP2426199A219 Oct 20077 Mar 2012Danisco US Inc.Polyol oxidases
EP2428522A117 May 200514 Mar 2012Agensys, Inc.Antibodies that bind to PSCA proteins for diagnosis of cancer
EP2441520A112 Oct 201018 Apr 2012Eppendorf AGReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
EP2444099A131 Mar 200625 Apr 2012Agensys, Inc.Antibodies and related molecules that bind to 161P2F10B proteins
EP2450456A22 Nov 20079 May 2012Yale UniversityAssessment of oocyte competence
EP2450702A228 Jan 20089 May 2012University Of Louisville Research Foundation, Inc.Methods of detecting autoantibodies for diagnosing and characterizing disorders
EP2460893A119 Jun 20066 Jun 2012Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2469282A17 Sep 200727 Jun 2012University of OxfordClinical diagnosis of hepatic fibrosis using a novel panel of human serum protein biomarkers
EP2469283A17 Sep 200727 Jun 2012University of OxfordClinical diagnosis of hepatic fibrosis using human serum APOL1 as biomarker.
EP2487187A23 Jan 200815 Aug 2012Institute for Research in BiomedicineHuman cytomegalovirus neutralising antibodies and use thereof
EP2500439A119 Jun 200619 Sep 2012Advanced Cell Diagnostics, Inc.Methods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
EP2508596A221 Feb 200310 Oct 2012Bayer HealthcareMN/CA IX-specific monoclonal antibodies generated from MN/CA IX-deficient mice and methods of use
EP2511708A12 Oct 200817 Oct 2012Affymetrix, Inc.Highly multiplexed particle-based assays
EP2520669A26 Feb 20067 Nov 2012GeneNews Inc.Mild osteoathritis biomarkers and uses thereof
EP2526968A226 Jan 200728 Nov 2012Biogen Idec MA Inc.Nogo receptor antagonists
EP2532746A226 Mar 200812 Dec 2012EnGeneIC Molecular Delivery Pty Ltd.Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells
EP2546359A17 Dec 200616 Jan 2013Novartis AGEffects of inhibitors of FGFR3 on gene transcription
EP2583981A217 May 200524 Apr 2013Agensys, Inc.Antibodies and related molecules that bind to PSCA proteins
EP2628752A113 Dec 200721 Aug 2013Merck Sharp & Dohme Corp.Engineered anti-TSLP antibody
EP2645106A24 Apr 20062 Oct 2013Biogen Idec MA Inc.Methods and products for evaluating an immune response to a therapeutic agent
EP2674440A25 Dec 200618 Dec 2013IBC Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
EP2679599A120 Feb 20091 Jan 2014Amgen Inc.Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof
EP2700723A26 Aug 200826 Feb 2014Orion Genomics, LLCNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene
EP2711434A119 Jun 200626 Mar 2014Advanced Cell Diagnostics, Inc.Multiplex detection of nucleic acids
EP2712620A16 Feb 20092 Apr 2014Cornell UniversityMethods for Preventing or Treating Insulin Resistance
WO1979000882A1 *2 Apr 19791 Nov 1979Syva CoMacromolecular environment control in specific receptor assays
WO1980002800A1 *20 Jun 198024 Dec 1980A KestonSpecific impending ovulation indicator
WO1981000261A1 *23 Apr 19805 Feb 1981Syva CoCharge effects in immunoassays
WO1981001414A1 *19 Nov 198028 May 1981Charles Hospital DevAn improved method of non homogenous enzyme immunoassay
WO1985001747A1 *17 Oct 198425 Apr 1985Inomedix IncDevice for rapid quantitative analysis of a fluid
WO1985004397A119 Mar 198510 Oct 1985OncogenPlatelet related growth regulator
WO1997001097A1 *19 Jun 19969 Jan 1997Serex IncReceptor:release ligand (reland) complexes and assays and kits based thereon
WO1999045124A23 Mar 199910 Sep 1999Genencor IntModified forms of pullulanase
WO1999064447A1 *7 Jun 199916 Dec 1999Immco DiagnosticsSolution-phase elisa
WO2000015824A115 Mar 199923 Mar 2000Lars BrandenTransfer method for specific cellular localisation of nucleic acids
WO2000073451A130 May 20007 Dec 2000Schering CorpMammalian receptor proteins; related reagents and methods
WO2002020569A27 Sep 200114 Mar 2002Schering CorpMammalian genes; related reagents and methods
WO2003030835A211 Oct 200217 Apr 2003Schering CorpUse of bispecific antibodies to regulate immune responses
WO2003043524A220 Nov 200230 May 2003Univ MissouriCompositions and methods for accurate early pregnancy diagnosis
WO2003046201A21 Oct 20025 Jun 2003Kimberly Clark CoDetection and identification of enteric bacteria
WO2004037251A123 Oct 20036 May 2004Sterix LtdInhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 and type 2
WO2004096157A25 Mar 200411 Nov 2004New England Medical Center IncTreatment of igai deposition diseases
WO2005016282A213 Aug 200424 Feb 2005Joanne I AdamkewiczPrkcs as modifiers of the beta catenin pathway and methods of use
WO2005019409A215 Jul 20033 Mar 2005George GeorgiouCombinatorial protein library screening by periplasmic expression
WO2005048771A115 Nov 20042 Jun 2005Atsushi TakahashiResin twisting brush
WO2005058864A113 Dec 200430 Jun 2005Dade Behring IncAssay for entactogens
WO2005061482A113 Dec 20047 Jul 2005Dade Behring IncEcstasy haptens and immunogens
WO2005118864A217 May 200515 Dec 2005Agensys IncAntibodies and related molecules that bind to psca proteins
WO2006024694A25 Sep 20059 Mar 2006Licentia OyPeptide inhibitors of hk2 and their use
WO2006034048A216 Sep 200530 Mar 2006Univ MarylandTherapeutic agents targeting the ncca-atp channel and methods of use thereof
WO2006043178A217 Oct 200527 Apr 2006DaniscoEnzymes
WO2006107962A24 Apr 200612 Oct 2006Biogen Idec IncMethods and products for evaluating an immune response to a therapeutic protein
WO2006116727A227 Apr 20062 Nov 2006Dade Rehring IncCompositions and methods for detection of sirolimus
WO2007001986A219 Jun 20064 Jan 2007Yuling LuoMethods of detecting nucleic acids in individual cells and of identifying rare cells from large heterogeneous cell populations
WO2007088051A226 Jan 20079 Aug 2007Bayer Schering Pharma AgModulation of mdl-1 activity for treatment of inflammatory disease
WO2007124299A217 Apr 20071 Nov 2007Novartis AgAntagonist anti-cd40 antibody pharmaceutical compositions
WO2008005429A22 Jul 200710 Jan 2008Charles David AdairComposition for modulating the expression of cell adhesion molecules
WO2008010934A210 Jul 200724 Jan 2008Chemocentryx IncTriazolyl phenyl benzenesulfonamides
WO2008043566A211 Oct 200717 Apr 2008Janssen Pharmaceutica NvCompositions and methods for treating and diagnosing irritable bowel syndrome
WO2008051761A217 Oct 20072 May 2008Abbott LabAssay for cardiac troponin autoantibodies
WO2008067547A230 Nov 20075 Jun 2008Res Dev FoundationImproved immunoglobulin libraries
WO2008076321A113 Dec 200726 Jun 2008Schering CorpEngineered anti-tslp antibody
WO2008084410A23 Jan 200817 Jul 2008Humabs LlcHuman cytomegalovirus neutralising antibodies and use thereof
WO2008110006A112 Mar 200818 Sep 2008Douglas BarkerBiomarkers of prostate cancer and uses thereof
WO2008124670A27 Apr 200816 Oct 2008Becton Dickinson CoCompositions and methods for the identification of a carbapenemase gene
WO2008137475A230 Apr 200813 Nov 2008Res Dev FoundationImmunoglobulin fc libraries
WO2009021054A26 Aug 200812 Feb 2009Orion Genomics LlcNovel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the igf2 gene
WO2009032477A28 Aug 200812 Mar 2009Univ TexasVegfr-1/nrp-1 targeting peptides
WO2009038847A118 Jun 200826 Mar 2009Chemocentryx IncN-(2-(hetaryl)aryl)arylsulfonamides and n-(2-(hetaryl)hetaryl)arylsulfonamides
WO2010065437A130 Nov 200910 Jun 2010Research Development FoundationModulation of olfml-3 mediated angiogenesis
WO2010066252A19 Dec 200917 Jun 2010Dako Denmark A/SMethod for evaluating pre-treatment
WO2010068757A110 Dec 200917 Jun 2010The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesCompositions and methods useful for detecting and treating diseases associated with 16p chromosomal disruptions
WO2010093820A211 Feb 201019 Aug 2010Orion Genomics LlcCombinations of polymorphisms for determining allele-specific expression of igf2
WO2010096658A119 Feb 201026 Aug 2010The Cleveland Clinic FoundationCorin as a marker for heart failure
WO2010104683A1 *25 Feb 201016 Sep 2010Siemens Healthcare Diagnostics Inc.Immunoassays employing non-particulate chemiluminescent reagent
WO2010126670A226 Mar 20104 Nov 2010Gojo Industries, Inc.Compositions and methods for screening and using compounds antagonizing spore-surface interactions
WO2010134035A119 May 201025 Nov 2010Danisco A/SUse
WO2010141421A11 Jun 20109 Dec 2010The Board Of Regents Of The University Of Texas SystemIdentification of small molecules recognized by antibodies in subjects with neurodegenerative diseases
WO2010150213A123 Jun 201029 Dec 2010Danisco A/SProtein
WO2011002834A230 Jun 20106 Jan 2011American Type Culture CollectionCompositions and methods for diagnosis and treatment of type 1 diabetes
WO2011008780A113 Jul 201020 Jan 2011Accumetrics, Inc.Apparatus and methods for processing a whole blood sample
WO2011019423A214 May 201017 Feb 2011Schering CorporationModulation of pilr receptors to treat microbial infections
WO2011038403A128 Sep 201031 Mar 2011Yuling LuoMethods of detecting nucleic acid sequences with high specificity
WO2011044186A16 Oct 201014 Apr 2011The Board Of Trustees Of The University Of IllinoisHuman single-chain t cell receptors
WO2011056688A227 Oct 201012 May 2011Caris Life Sciences, Inc.Molecular profiling for personalized medicine
WO2011061657A18 Nov 201026 May 2011Danisco A/SMethod
WO2011063198A219 Nov 201026 May 2011St. Jude Children's Research HospitalMethods and compositions for modulating the activity of the interleukin-35 receptor complex
WO2011068676A117 Nov 20109 Jun 2011Abbott LaboratoriesPeptide reagents and method for inhibiting autoantibody antigen binding
WO2011068680A117 Nov 20109 Jun 2011Abbott LaboratoriesAssay for diagnosis of cardiac myocyte damage
WO2011068681A117 Nov 20109 Jun 2011Abbott LaboratoriesASSAY FOR CARDIAC TROPONIN-T (cTnT)
WO2011076881A122 Dec 201030 Jun 2011Arabian Gulf UniversityMutant ldl receptor gene
WO2011084357A110 Dec 201014 Jul 2011Schering CorporationModulation of pilr to treat immune disorders
WO2011092700A127 Jan 20114 Aug 2011Yeda Research And Development Co. Ltd.Antibodies that inhibit metalloproteins
WO2011094669A131 Jan 20114 Aug 2011Advanced Cell Diagnostics, Inc.Methods of in situ detection of nucleic acids
WO2011096926A14 Feb 201011 Aug 2011Massachusetts Institute Of TechnologyMethods for preparing sequencing libraries
WO2011114251A11 Mar 201122 Sep 2011Danisco A/SFoodstuff
WO2011140234A14 May 201110 Nov 2011Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2012004759A27 Jul 201112 Jan 2012Danisco A/SMethod
WO2012006056A228 Jun 201112 Jan 2012Oregon Health & Science UniversityCcr6 as a biomarker of alzheimer's disease
WO2012007537A113 Jul 201119 Jan 2012Dublin City UniversityDirect clone analysis and selection technology
WO2012009627A215 Jul 201119 Jan 2012Vanderbilt UniversityLow resource processor using surface tension valves for extracting, concentrating and detecting molecular species
WO2012018476A18 Jul 20119 Feb 2012Abbott Japan Co. Ltd.Antibodies relating to pivka-ii and uses thereof
WO2012019012A14 Aug 20119 Feb 2012Idexx Laboratories, Inc.Detection of degradation products of canine nt-probnp
WO2012040168A220 Sep 201129 Mar 2012Advanced Cell Diagnostics, Inc.Biomarkers for differentiating melanoma from benign nevus in the skin
WO2012049066A26 Oct 201119 Apr 2012Eppendorf AgReal-time amplification and micro-array based detection of nucleic acid targets in a flow chip assay
WO2012054795A121 Oct 201126 Apr 2012Advanced Cell Diagnostics, Inc.An ultra sensitive method for in situ detection of nucleic acids
WO2012075111A130 Nov 20117 Jun 2012Novartis AgUses of anti-cd40 antibodies in combination therapy for b cell-related cancers
WO2012099896A217 Jan 201226 Jul 2012Life Technologies CorporationWorkflow for detection of ligands using nucleic acids
WO2012103414A227 Jan 20122 Aug 2012Advanced Cell Diagnostics, Inc.Rnascope® hpv assay for determining hpv status in head and neck cancers and cervical lesions
WO2012109133A16 Feb 201216 Aug 2012Research Development FoundationEngineered immunoglobulin fc polypeptides
WO2012120377A28 Mar 201213 Sep 2012King Abdullah University Of Science And TechnologyMolecular biomarker set for early detection of ovarian cancer
WO2012125582A112 Mar 201220 Sep 2012Board Of Regents Of The University Of NebraskaBiomarker for coronary artery disease
WO2012131594A128 Mar 20124 Oct 2012Novartis AgMarkers associated with cyclin-dependent kinase inhibitors
WO2012137147A14 Apr 201211 Oct 2012Danisco Us, Inc.Compositions
WO2012150959A19 Nov 20118 Nov 2012Abbott LaboratoriesMethods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor
WO2013010170A116 Jul 201217 Jan 2013Lovell Mark AProcess for detection of alzheimer's disease from a serum sample
WO2013011347A118 Jul 201124 Jan 2013Institute For Research In BiomedicineNeutralizing anti-influenza a virus antibodies and uses thereof
WO2013012924A218 Jul 201224 Jan 2013President And Fellows Of Harvard CollegeEngineered microbe-targeting molecules and uses thereof
WO2013022599A125 Jul 201214 Feb 2013Research Development FoundationImproved methods and compositions for modulation of olfml3 mediated angiogenesis
WO2013101758A121 Dec 20124 Jul 2013Baylor Research InstituteBiomarkers for kawasaki disease
WO2013130811A128 Feb 20136 Sep 2013Chemocentryx, Inc.Pyrazol-1-yl benzene sulfonamides as ccr9 antagonists
WO2013140247A114 Mar 201326 Sep 2013Humabs Biomed SaAntibodies that neutralize rsv, mpv and pvm and uses thereof
WO2013163035A119 Apr 201331 Oct 2013Uhl Ii, LlcDevices and methods for detecting analyte in bodily fluid
WO2014011398A126 Jun 201316 Jan 2014Novartis AgBiomarkers associated with cdk inhibitors
WO2014014788A212 Jul 201323 Jan 2014President And Fellows Of Harvard CollegeModification of surfaces for simulataneous repellency and targeted binding of desired moieties
WO2014020502A225 Jul 20136 Feb 2014Novartis AgMarkers associated with human double minute 2 inhibitors
WO2014063097A118 Oct 201324 Apr 2014Danisco Us Inc.Stabilization of biomimetic membranes
Classifications
U.S. Classification435/7.9, 435/188, 930/260, 436/546, 930/40
International ClassificationG01N33/94, G01N33/542
Cooperative ClassificationG01N33/542, G01N33/9486, G01N33/948, G01N33/946, Y10S930/26
European ClassificationG01N33/94H, G01N33/94P, G01N33/94N, G01N33/542
Legal Events
DateCodeEventDescription
27 Apr 2005ASAssignment
Owner name: DADE MICROSCAN INC., ILLINOIS
Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH;REEL/FRAME:015953/0315
Effective date: 20050426
Owner name: SYVA COMPANY, ILLINOIS
Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH;REEL/FRAME:015953/0326
Owner name: DADE MICROSCAN INC. 1717 DEERFIELD ROADDEERFIELD,
Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH /AR;REEL/FRAME:015953/0315
Owner name: SYVA COMPANY 1717 DEERFIELD ROADDEERFIELD, ILLINOI
Free format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:DEUTSCHE BANK AG, NEW YORK BRANCH /AR;REEL/FRAME:015953/0326
4 Dec 2002ASAssignment
Owner name: DEUTSCHE BANK AG, NEW YORK
Free format text: SECURITY AGREEMENT;ASSIGNOR:SYVA COMPANY;REEL/FRAME:013542/0411
Effective date: 20021001
Owner name: DEUTSCHE BANK AG 31 WEST 52ND STREETNEW YORK, NEW
22 Nov 2002ASAssignment
Owner name: DEUTSCHE BANK AG, NEW YORK
Free format text: SECURITY AGREEMENT;ASSIGNOR:DADE MICROSCAN INC.;REEL/FRAME:013599/0629
Effective date: 20021003
Free format text: ;ASSIGNOR:DADE MICROSCAN INC.;REEL/FRAME:013516/0250
Effective date: 20021001
Owner name: DEUTSCHE BANK AG 31 WEST 52ND STREETNEW YORK, NEW
Free format text: ;ASSIGNOR:DADE MICROSCAN INC. /AR;REEL/FRAME:013516/0250
Owner name: DEUTSCHE BANK AG 31 WEST 52ND STREETNEW YORK, NEW
Free format text: SECURITY AGREEMENT;ASSIGNOR:DADE MICROSCAN INC. /AR;REEL/FRAME:013599/0629